[go: up one dir, main page]

WO2019180189A1 - Dérivés d'aminopropoxyphényle et de benzyl 3,4-dihydro-2h-spiro[isoquinoline-1,4'-pipéridine]-1'-yl ayant une activité multimodale contre la douleur - Google Patents

Dérivés d'aminopropoxyphényle et de benzyl 3,4-dihydro-2h-spiro[isoquinoline-1,4'-pipéridine]-1'-yl ayant une activité multimodale contre la douleur Download PDF

Info

Publication number
WO2019180189A1
WO2019180189A1 PCT/EP2019/057186 EP2019057186W WO2019180189A1 WO 2019180189 A1 WO2019180189 A1 WO 2019180189A1 EP 2019057186 W EP2019057186 W EP 2019057186W WO 2019180189 A1 WO2019180189 A1 WO 2019180189A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
alkyl
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2019/057186
Other languages
English (en)
Inventor
Carmen ALMANSA-ROSALES
Marina VIRGILI-BERNADO
Monica Alonso-Xalma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Esteve Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals SA filed Critical Esteve Pharmaceuticals SA
Publication of WO2019180189A1 publication Critical patent/WO2019180189A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Definitions

  • the present invention relates to compounds having dual pharmacological activity towards both the a 2 d subunit of the voltage-gated calcium channel, and the m-opioid receptor (MOR or mu-opioid receptor) and more particularly to aminopropoxyphenyl and benzyl 3,4-dihydro-2/-/-spiro[isoquinoline-1 ,4'-piperidin]-T-yl derivatives having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.
  • MOR m-opioid receptor
  • NSAIDs non-steroidal anti- inflammatory drugs
  • opioid agonists opioid agonists
  • calcium channel blockers and antidepressants
  • antidepressants but they are much less than optimal regarding their safety ratio. All of them show limited efficacy and a range of secondary effects that preclude their use, especially in chronic settings.
  • Voltage-gated calcium channels are required for many key functions in the body. Different subtypes of voltage-gated calcium channels have been described (Zamponi et al., Pharmacol Rev. 2015 67:821-70).
  • the VGCC are assembled through interactions of different subunits, namely oti (Ca v oti), b (Ca v p) a 2 d (Ca v a 2 6) and g (Ca v y).
  • the oti subunits are the key porous forming units of the channel complex, being responsible for the Ca 2+ conduction and generation of Ca 2+ influx.
  • VGCC can be subdivided into low voltage-activated T-type (Ca v 3.1 , Ca v 3.2, and Ca v 3.3), and high voltage-activated L- (Ca v 1.1 through Ca v 1.4), N-(Ca v 2.2), P/Q-(Ca v 2.1 ), and R- (Ca v 2.3) types, depending on the channel forming Cava subunits.
  • Current therapeutic agents include drugs targeting L-type Ca v 1.2 calcium channels, particularly 1 ,4-dihydropyridines, which are widely used in the treatment of hypertension.
  • T-type (Ca v 3) channels are the target of ethosuximide, widely used in absence epilepsy.
  • Ziconotide a peptide blocker of N-type (Ca v 2.2) calcium channels, has been approved as a treatment of intractable pain. (Perret and Luo, 2009, supra, Vink and Alewood, Br J Pharmacol. 2012 167:970-89.).
  • the Ca v 1 and Ca v 2 subfamilies contain an auxiliary a d subunit, which is the therapeutic target of the gabapentinoid drugs of value in certain epilepsies and chronic neuropathic pain.
  • a d subunit which encoded by a unique gene and all possessing splice variants.
  • Each a d protein is encoded by a single messenger RNA and is post-translationally cleaved and then linked by disulfide bonds.
  • Four genes encoding a2d subunits have now been cloned.
  • a 2 d-1 was initially cloned from skeletal muscle and shows a fairly ubiquitous distribution.
  • the a 2 d-2 and a 2 d-3 subunits were subsequently cloned from brain.
  • the most recently identified subunit, a 2 d-4 is largely non-neuronal.
  • the human a 2 d-4 protein sequence shares 30, 32 and 61% identity with the human a 2 d-1 , a 2 d-2 and a 2 d-3 subunits, respectively.
  • the gene structure of all a 2 d subunits is similar. All a 2 d subunits show several splice variants (Davies et al., Trends Pharmacol Sci. 2007 28:220-8.; Dolphin AC, Nat Rev Neurosci. 2012 13:542-55., Biochim Biophys Acta. 2013 1828:1541-9.).
  • the Ca v ot 2 8-1 subunit may play an important role in neuropathic pain development (Perret and Luo, 2009, supra ; Vink and Alewood, 2012, supra).
  • Biochemical data have indicated a significant Ca v a, 2 8-1 , but not Ca v a, 2 8-2, subunit upregulation in the spinal dorsal horn, and DRG (dorsal root ganglia) after nerve injury that correlates with neuropathic pain development.
  • the Ca v ot 2 8-1 subunit (and the Ca v ot 2 8-2, but not Ca v ot 2 8-3 and Ca v ot 2 8-4, subunits) is the binding site for gabapentin which has anti-allodynic/ hyperalgesic properties in patients and animal models.
  • injury-induced Ca v ot 2 8-1 expression correlates with neuropathic pain development and maintenance, and various calcium channels are known to contribute to spinal synaptic neurotransmission and DRG neuron excitability
  • injury-induced Ca v ot 2 8-1 subunit upregulation may contribute to the initiation and maintenance of neuropathic pain by altering the properties and/or distribution of VGCC in the subpopulation of DRG neurons and their central terminals, therefore modulating excitability and/or synaptic neuroplasticity in the dorsal horn.
  • Intrathecal antisense oligonucleotides against the Ca v ot 2 8-1 subunit can block nerve injury-induced Ca v ot 2 8-1 upregulation and prevent the onset of allodynia and reserve established allodynia.
  • the 0, 2 8 subunits of VGCC form the binding site for gabapentin and pregabalin, which are structural derivatives of the inhibitory neurotransmitter GABA although they do not bind to GABAA, GABAB, or benzodiazepine receptors, or alter GABA regulation in animal brain preparations.
  • the binding of gabapentin and pregabalin to the Ca v ot 2 8 subunit results in a reduction in the calcium-dependent release of multiple neurotransmitters, leading to efficacy and tolerability for neuropathic pain management.
  • Gabapentinoids may also reduce excitability by inhibiting synaptogenesis (Perret and Luo, 2009, supra ; Vink and Alewood, 2012, supra, Zamponi et al., 2015, supra).
  • opioids are among the most effective, especially when addressing severe pain states. They act through three different types of opioid receptors (mu, kappa and gamma) which are transmembrane G-protein coupled receptors (GPCRs). Still, the main analgesic action is attributed to the activation of the m-opioid receptor (MOR).
  • MOR agonists are not optimal for the treatment of chronic pain as indicated by the diminished effectiveness of morphine against chronic pain conditions. This is especially proven for the chronic pain conditions of neuropathic or inflammatory origin, in comparison to its high potency against acute pain.
  • Polypharmacology is a phenomenon in which a drug binds multiple rather than a single target with significant affinity.
  • the effect of polypharmacology on therapy can be positive (effective therapy) and/or negative (side effects). Positive and/or negative effects can be caused by binding to the same or different subsets of targets; binding to some targets may have no effect.
  • Multi-component drugs or multi-targeting drugs can overcome toxicity and other side effects associated with high doses of single drugs by countering biological compensation, allowing reduced dosage of each compound or accessing context-specific multitarget mechanisms. Because multitarget mechanisms require their targets to be available for coordinated action, one would expect synergies to occur in a narrower range of cellular phenotypes given differential expression of the drug targets than would the activities of single agents.
  • multi-targeting drugs may produce concerted pharmacological intervention of multiple targets and signaling pathways that drive pain. Because they actually make use of biological complexity, multi-targeting (or multi-component drugs) approaches are among the most promising avenues toward treating multifactorial diseases such as pain (Gilron et al., Lancet Neurol. 2013 Nov;12(11 ):1084-95.).
  • positive synergistic interaction for several compounds, including analgesics has been described (Schroder et al., J Pharmacol Exp Ther. 201 1 ; 337:312-20. Erratum in: J Pharmacol Exp Ther. 2012; 342:232.; Zhang et al., Cell Death Dis. 2014; 5:e1 138.; Gilron et al., 2013, supra).
  • An alternative strategy for multitarget therapy is to design a single compound with selective polypharmacology (multi-targeting drug). It has been shown that many approved drugs act on multiple targets. Dosing with a single compound may have advantages over a drug combination in terms of equitable pharmacokinetics and biodistribution. Indeed, troughs in drug exposure due to incompatible pharmacokinetics between components of a combination therapy may create a low- dose window of opportunity where a reduced selection pressure can lead to drug resistance. In terms of drug registration, approval of a single compound acting on multiple targets faces significantly lower regulatory barriers than approval of a combination of new drugs (Hopkins, 2008, supra). Thus, the present application, relates to the advantages of having dual activity, for m- receptor and the a 2 d-1 subunit of voltage-gated calcium channels, in the same molecule to treat chronic pain.
  • the present invention relates to compounds having a complementary dual mechanism of action (m-receptor agonist and blocker of the a 2 d subunit, in particular the a 2 d-1 subunit, of voltage-gated calcium channels) which implies a better profile of tolerability than the strong opioids (morphine, oxycodone, fentanyl etc) and/or better efficacy and tolerability than gabapentinoids (pregabalin and gabapentin).
  • m-receptor agonist and blocker of the a 2 d subunit, in particular the a 2 d-1 subunit, of voltage-gated calcium channels which implies a better profile of tolerability than the strong opioids (morphine, oxycodone, fentanyl etc) and/or better efficacy and tolerability than gabapentinoids (pregabalin and gabapentin).
  • Pain is multimodal in nature, since in nearly all pain states several mediators, signaling pathways and molecular mechanisms are implicated. Consequently, monomodal therapies fail to provide complete pain relief.
  • therapies are a common clinical practice and many efforts are directed to assess the best combination of available drugs in clinical studies (Mao, J., Gold, M.S., Backonja, M.; 201 1 ; J. Pain; 12; 157-166).
  • the present invention offers a solution by combining in a single compound binding to two different targets relevant for the treatment of pain. This was mainly achieved by providing the compounds according to the invention that bind both to the m-opioid receptor and to the a 2 d subunit, in particular the a 2 d-1 subunit, of the voltage- gated calcium channel.
  • the main object of the invention is directed to a compound having a dual activity binding to the a 2 d subunit, in particular the a 2 d-1 subunit, of the voltage-gated calcium channel and the m-opioid receptor for use in the treatment of pain.
  • this invention is aimed at providing a compound or a chemically related series of compounds which act as dual ligands of the a 2 d subunit, in particular the a 2 d-1 subunit, of the voltage-gated calcium channel and the m-opioid receptor it is a very preferred embodiment if the compound has a binding expressed as K, responding to the following scales:
  • K ⁇ (m) is preferably ⁇ 1000 nM, more preferably ⁇ 500 nM, even more preferably ⁇ 100 nM.
  • K,(a 2 d-1 ) is preferably ⁇ 10000 nM, more preferably ⁇ 5000 nM, even more preferably ⁇ 500 nM or even more preferably ⁇ 100 nM.
  • the invention is directed in a main aspect to a compound of general Formula (I),
  • Ri, R 2 , R3, R3', R 4 , R 4 ⁇ , X, Ui, Y2 and n are as defined below in the detailed description.
  • a further object of the invention refers to the processes for preparation of compounds of general formula (I).
  • a still further object of the invention refers to the use of intermediate compounds for the preparation of a compound of general formula (I).
  • the main object of the invention is directed to a compound having a dual activity binding to the a 2 d subunit, in particular the a 2 d-1 subunit, of the voltage-gated calcium channel and the m-opioid receptor, for use in the treatment of pain.
  • this invention is aimed at providing a compound or a chemically related series of compounds which act as dual ligands of the a 2 d subunit, in particular the a 2 d-1 subunit, of the voltage-gated calcium channel and the m-opioid receptor, it is a very preferred embodiment if the compound has a binding expressed as K, responding to the following scales:
  • K ⁇ (m) is preferably ⁇ 1000 nM, more preferably ⁇ 500 nM, even more preferably ⁇ 100 nM.
  • K,(a 2 d-1 ) is preferably ⁇ 10000 nM, more preferably ⁇ 5000 nM, even more preferably ⁇ 500 nM or even more preferably ⁇ 100 nM.
  • the applicant has surprisingly found that the problem of providing a new effective and alternative for treating pain and pain related disorders can be solved by using a multimodal balanced analgesic approach combining two different synergistic activities in a single drug (i.e., dual ligands which are bifunctional and bind to m-opioid receptor and to a 2 d subunit, in particular the a 2 d-1 subunit, of the voltage-gated calcium channel), thereby enhancing through the a 2 d blockade without increasing the undesirable side effects.
  • This supports the therapeutic value of a dual agent, whereby the a 2 d binding component acts as an intrinsic adjuvant of the MOR binding component.
  • a dual compound that possess binding to both the m-opioid receptor and to the a 2 d subunit of the voltage-gated calcium channel shows a highly valuable therapeutic potential by achieving an outstanding analgesia (enhanced in respect to the potency of the opioid component alone) with a reduced side-effect profile (safety margin increased compared to that of the opioid component alone) versus existing opioid therapies.
  • the dual compounds according to the present invention would in addition show one or more the following functionalities: blockade of the a 2 d subunit, in particular the a 2 d-1 subunit, of the voltage-gated calcium channel and m-opioid receptor agonism
  • An antagonist blocks or dampens agonist-mediated responses.
  • Known subfunctionalities are neutral antagonists or inverse agonists.
  • An agonist increases the activity of the receptor above its basal level.
  • Known subfunctionalities are full agonists, or partial agonists.
  • the two mechanisms complement each other since MOR agonists are only marginally effective in the treatment of neuropathic pain, while the blockers of the a 2 d subunit, in particular the a 2 d-1 subunit, of voltage-gated calcium channels show outstanding effects in preclinical neuropathic pain models.
  • the a 2 d component in particular the a 2 d-1 component, adds unique analgesic actions in opioid-resistant pain.
  • the dual approach has clear advantages over MOR agonists in the treatment of chronic pain as lower and better tolerated doses would be needed based on the potentiation of analgesia but not of the adverse events of MOR agonists.
  • a further advantage of using designed multiple ligands is a lower risk of drug-drug interactions compared to cocktails or multi-component drugs, thus involving simpler pharmacokinetics and less variability among patients. Additionally, this approach may improve patient compliance and broaden the therapeutic application in relation to monomechanistic drugs, by addressing more complex aetiologies. It is also seen as a way of improving the R&D output obtained using the“one drug-one target” approach, which has been questioned over the last years [Bornot A, Bauer U, Brown A, Firth M, Hellawell C, Engkvist O. Systematic Exploration of Dual-Acting Modulators from a Combined Medicinal Chemistry and Biology Perspective. J. Med. Chem, 56, 1197- 1210 (2013)].
  • Ri, R 2 , R3, R3', R 4 , R 4 ⁇ , X, Yi, Y 2 , and n are as defined in the detailed description, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound of general Formula (I)
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -;
  • R a is selected from hydrogen, halogen, substituted or unsubstituted C alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl
  • Rb is selected from hydrogen, halogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl and substituted or unsubstituted C2-6 alkynyl; alternatively, R a and R b , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl;
  • R z is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci-6 alkyl; p is 0, 1 , 2, 3, 4 or 5; q is 0, 1 , 2, 3, 4 or 5;
  • n 0 or 1 ;
  • Yi is -C(RioRio')-; wherein R 10 and Rio ⁇ are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10 and Re form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl;
  • Y 2 is -C(Rio”Rio )-; wherein Rio- and R-io- are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10” and Rio- form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl;
  • R 5 and R 5' are independently selected from halogen, -R 51 , -OR 51 , -NO 2 , - NR 51 R 51 ' , -NR 5i C(0)R 5r , -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 r, - NR 5i C(0)NR 5 rR 5i ⁇ , -
  • R 51 , Rsr and Rsr are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl;
  • R 6 is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R7;
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl;
  • R 2 is selected from substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl
  • R 3 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted alkylcycloalkyl;
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl;
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -NO2, - NR 4i R 4 r, -NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 rR 4 -r, -SR 4 I , -S(0)R 4 I , -S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , - C(0)NR 4i R 4 r, -0CH 2 CH 2 0R 4 I , -NR 4i S(0) 2 NR 4 R 4i” and -C(CH 3 ) 2 0R 4 I ; wherein R 4 I , R 4 r and R 4 r are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubsti
  • These compounds according to the invention are optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • these compounds according to the invention are optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof.
  • “or a corresponding salt thereof” does also mean “or a corresponding pharmaceutically acceptable salt thereof. This does apply to all below described embodiments and uses of“salt” being thus equivalent to“pharmaceutically acceptable salt”.
  • the compound according to the invention is a compound of general Formula (I)
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -;
  • R a is selected from hydrogen, halogen, substituted or unsubstituted C alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl;
  • R b is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R a and R b , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl;
  • R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; p is 0, 1 , 2, 3, 4 or 5; q is 0, 1 , 2, 3, 4 or 5; n is 0 or 1 ;
  • Yi is -C(RioRio')-; wherein R 10 and Rio ⁇ are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10 and R-io form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl;
  • Y2 is -C(Rio”Rio'”)-; wherein Rio- and R 10 - are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10” and Rio- form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl;
  • R5 and R5' are independently selected from halogen, -R51, -OR51, -NO2, - NR51R51', -NR 5i C(0)R 5r , -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 -r, - NR 5i C(0)NR 5i R 5i” , - SR51 , -S(0)R5i, -S(0)2R5i, -CN, haloalkyl, haloalkoxy, -C(0)ORsi, - C(0)NR 5i R 5 , -OCH 2 CH 2 OR 5I , -NR 5i S(0) 2 NR 5 rR 5 r and -C(CH 3 ) 2 OR 5I ; wherein R 51 , Rsr and R 5 r are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or
  • R 6 is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R7; wherein the alkyl, alkenyl or alkynyl defined in R 6 , if substituted, is substituted with one or more substituent/s selected from -OR61, halogen, -CN, haloalkyl, haloalkoxy and -NReiRer; wherein the cycloalkyl, aryl and heterocyclyl defined
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl; wherein the alkyl, alkenyl or alkynyl defined in R 7 , if substituted, is substituted with one or more substituent/s selected from -OR71, halogen, -CN, haloalkyl, haloalkoxy and -NR71R71'; wherein the cycloalkyl, aryl and heterocyclyl, as defined in R 7 , also in
  • R 21 , R 21' and R 21” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl;
  • NR3iS(0) 2 NR 3 rR3r' and -C(CH3)20R3i preferably selected from halogen, -R31, -OR31, -NR31R31', -CN, haloalkyl and haloalkoxy; wherein R 31 , R 31' and R 31” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl;
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; wherein, the alkyl, alkenyl or alkynyl defined in R 3' , if substituted, is substituted with one or more substituent/s selected from -OR 32 , halogen, -CN, haloalkyl, haloalkoxy and -NR32R32'; wherein R 32 and R 32' are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl;
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -NO 2 , - NR 4i R 4 r, -NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 rR 4 -r, -SR 4 I , -S(0)R 4 I , -S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , - C(0)NR 4i R 4 r, -0CH 2 CH 2 0R 4 I , -NR 4i S(0) 2 NR 4 R 4i” and -C(CH 3 ) 2 0R 4 I ; wherein R 4 I , R 4 r and R 4 r are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or
  • R14, Ru ⁇ and R-u- are independently selected from hydrogen, unsubstituted C1-6 alkyl, unsubstituted C2-6 alkenyl, unsubstituted C2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound of general Formula (I )
  • Ri, R 2 , R3, R3', R 4 , R 4 ⁇ , X and n are as defined in the detailed description, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound of general Formula (I )
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -;
  • R a is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C2-6 alkenyl and substituted or unsubstituted C2-6 alkynyl;
  • Rb is selected from hydrogen, halogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl and substituted or unsubstituted C2-6 alkynyl; alternatively, R a and R b , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl;
  • R z is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci-6 alkyl; p is 0, 1 , 2, 3, 4 or 5; q is 0, 1 , 2, 3, 4 or 5;
  • n 0 or 1 ;
  • R1 is wherein m is 0, 1 or 2; r is 0, 1 or 2;
  • R 5 and R 5' are independently selected from halogen, -R 51 , -OR 51 , -NO 2 , - NR 51 R 51 ' , -NR 5i C(0)R 5r , -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 -r, - NR 5i C(0)NR 5i R 5i” , - SR51 , -S(0)R5i, -S(0)2R5i, -CN, haloalkyl, haloalkoxy, -C(0)0Rsi, - C(0)NR 5i R 5 r, -OCH 2 CH 2 OR 5 I , -NR 5i S(0) 2 NR 5 rR 5i and -C(CH 3 ) 2 OR 5 I ; wherein R 51 , Rsr and R 5 r are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 al
  • R 6 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R7;
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl;
  • R 2 is selected from substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl
  • R 3 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted alkylcycloalkyl;
  • R3' is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl;
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -NO2, - NR 4i R 4 r, -NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 rR 4 -r, -SR 4 I , -S(0)R 4 I , -S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , - C(0)NR 4i R 4 r, -0CH 2 CH 2 0R 4 I , -NR 4i S(0) 2 NR 4 R 4i” and -C(CH 3 ) 2 0R 4 I ; wherein R 4 I , R 4 r and R 4 r are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubsti
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound of general Formula (I )
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -;
  • R a is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl;
  • R b is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R a and R b , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl;
  • R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; p is 0, 1 , 2, 3, 4 or 5; q is 0, 1 , 2, 3, 4 or 5;
  • n 0 or 1 ;
  • R5 and R5' are independently selected from halogen, -R51, -OR51, -NO2, - NR51R51', -NR 5i C(0)R 5r , -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 -r, - NR 5i C(0)NR 5i R 5i” , - SR51 , -S(0)R5i, -S(0)2R5i, -CN, haloalkyl, haloalkoxy, -C(0)0Rsi, -
  • R51, Rsr and Rsr are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl;
  • R 6 is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R7; wherein the alkyl, alkenyl or alkynyl defined in R 6 , if substituted, is substituted with one or more substituent/s selected from -OR 61 , halogen, -CN, haloalkyl, haloalkoxy and -NRei Rer; wherein the cycloalkyl, aryl and heterocyclyl
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl; wherein the alkyl, alkenyl or alkynyl defined in R 7 , if substituted, is substituted with one or more substituent/s selected from -OR 71 , halogen, -CN, haloalkyl, haloalkoxy and -NR71R71'; wherein the cycloalkyl, aryl and heterocyclyl, as defined in R 7 ,
  • R 2 is selected from substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl, wherein the aryl or heterocyclyl in R 2 , if substituted, is substituted with one or more substituent/s selected from halogen, -R21, -OR21, -NO2, -NR21R21', - NR 2i C(0)R 2 r, -NR2iS(0)2R2 , -S(0)2NR2iR2r, - NR2iC(0)NR2i R2i”, -SR21 , - S(0)R2i, -S(0)2R2i, -CN, haloalkyl, haloalkoxy, -C(0)0R2i, -C(0)NR2iR2r, - OCH2CH2OR21, -NR2iS(0) 2 NR 2 rR2r' and -C(CH 3 ) 2 OR 2 I ; wherein R 21 , R
  • R3' is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; wherein, the alkyl, alkenyl or alkynyl defined in R3', if substituted, is substituted with one or more substituent/s selected from -OR 32 , halogen, -CN, haloalkyl, haloalkoxy and -NR32R32'; wherein R 32 and R 32' are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl;
  • R 4 and R 4' are independently selected from halogen, -R 4I , -OR 4I , -NO 2 , - NR 4i R 4 r, -NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 rR 4 -r, -SR 4I , -S(0)R 4I , -S(0) 2 R 4I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , - C(0)NR 4i R 4 r, -0CH 2 CH 2 0R 4I , -NR 4i S(0) 2 NR 4 R 4i” and -C(CH 3 ) 2 0R 4I ; wherein R 41 , R 41' and R 41” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubsti
  • Ri, R3, R3', R 4 , R 4 ⁇ , R9, R9', X, Ui, Y2 and n are as defined in the detailed description, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound of general Formula (l a )
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -;
  • R a is selected from hydrogen, halogen, substituted or unsubstituted C alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl
  • R b is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R a and R b , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl
  • R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted
  • Yi is -C(RioRio')-; wherein R 10 and Rio ⁇ are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10 and R-io form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl;
  • Y2 is -C(Rio”Rio'”)-; wherein Rio- and R 10 - are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10” and Rio- form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl;
  • R5 and R5' are independently selected from halogen, -R51, -OR51, -NO2, - NR51R51', -NR 5i C(0)R 5r , -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 -r, - NR 5i C(0)NR 5i R 5i” , - SR51 , -S(0)R5i, -S(0)2R5i, -CN, haloalkyl, haloalkoxy, -C(0)0Rsi, - C(0)NR 5i R 5 r, -OCH 2 CH 2 OR 5 I , -NR 5i S(0) 2 NR 5 rR 5i and -C(CH 3 ) 2 OR 5 I ; wherein R51, Rsr and R 5 r are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or
  • R 6 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R7;
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl;
  • R 3 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted alkylcycloalkyl;
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl;
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -NO 2 , - NR 4i R 4 r, -NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 rR 4 -r, -SR 4 I , -S(0)R 4 I , -S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , - C(0)NR 4i R 4 r, -0CH 2 CH 2 0R 4 I , -NR 4i S(0) 2 NR 4 R 4i” and -C(CH 3 ) 2 0R 4 I ; wherein R 4 I , R 4 r and R 4 r are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or
  • Rg and Rg ⁇ are independently selected from halogen, -R 21 , -OR 21 , -NO 2 , -
  • NR21R21 -NR 2i C(0)R 2 r, -NR2iS(0)2R2 , -S(0)2NR2iR2 , - NR2iC(0)NR2i R2i”, -SR21 , -S(0)R2i, -S(0)2R2i, -CN, haloalkyl, haloalkoxy, -C(0)0R2i, - C(0)NR 2i R 2 r, -OCH2CH2OR21, -NR2iS(0) 2 NR 2 rR2r' and -C(CH 3 ) 2 OR 2 I ; wherein R 21 , R 21' and R 21” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or di
  • the compound according to the invention of general Formula (I) is a compound of general Formula (l a )
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -;
  • R a is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl
  • R b is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R a and R b , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl
  • R z is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstit
  • n 0 or 1 ;
  • Yi is -C(RioRio')-; wherein R 10 and Rio ⁇ are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10 and Re form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl;
  • Y 2 is -C(Rio”Rio )-; wherein Rio- and R-io- are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10” and Rio- form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl;
  • R5 and R5' are independently selected from halogen, -R51, -OR51, -NO2, - NR51R51', -NR 5i C(0)R 5r , -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 -r, - NR 5i C(0)NR 5i R 5i” , - SR51 , -S(0)R5i, -S(0)2R5i, -CN, haloalkyl, haloalkoxy, -C(0)0Rsi, -
  • R51, Rsr and Rsr are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl;
  • R 6 is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R7; wherein the alkyl, alkenyl or alkynyl defined in R 6 , if substituted, is substituted with one or more substituent/s selected from -OR 61 , halogen, -CN, haloalkyl, haloalkoxy and -NRei Rer; wherein the cycloalkyl, aryl and heterocyclyl
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl; wherein the alkyl, alkenyl or alkynyl defined in R 7 , if substituted, is substituted with one or more substituent/s selected from -OR 71 , halogen, -CN, haloalkyl, haloalkoxy and -NR71R71'; wherein the cycloalkyl, aryl and heterocyclyl, as defined in R 7 ,
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; wherein, the alkyl, alkenyl or alkynyl defined in R 3' , if substituted, is substituted with one or more substituent/s selected from -OR32, halogen, -CN, haloalkyl, haloalkoxy and -NR32R32'; wherein R32 and R32' are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl;
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -NO2, - NR 4i R 4 r, -NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 rR 4 -r, -SR 4 I , -S(0)R 4 I , -S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , - C(0)NR 4i R 4 r, -0CH 2 CH 2 0R 4 I , -NR 4i S(0) 2 NR 4 R 4i” and -C(CH 3 ) 2 0R 4 I ; wherein R 4 I , R 4 r and R 4 r are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubsti
  • Rg and Rg ⁇ are independently selected from halogen, -R21, -OR21, -NO2, - NR21R21’, -NR 2i C(0)R 2 r, -NR2iS(0)2R2 , -S(0)2NR2iR2 , - NR2iC(0)NR2i R2i”, -SR21 , -S(0)R2i, -S(0)2R2i, -CN, haloalkyl, haloalkoxy, -C(0)0R2i, - C(0)NR 2i R 2 r, -OCH2CH2OR21, -NR2iS(0) 2 NR 2 rR2r' and -C(CH 3 ) 2 OR 2 I ; wherein R 21 , R 21' and R 21” are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C
  • R 14 , Ru ⁇ and R-u- are independently selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound of general Formula (l a ’)
  • Ri, R3, R3', R 4 , R 4 ⁇ , R9, RET, X and n are as defined in the detailed description, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound of general Formula (l a ’)
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -;
  • R a is selected from hydrogen, halogen, substituted or unsubstituted C alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl;
  • R b is selected from hydrogen, halogen, substituted or unsubstituted C alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R a and R b , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl;
  • R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; p is 0, 1 , 2, 3, 4 or 5; q is 0, 1 , 2, 3, 4 or 5;
  • n 0 or 1 ;
  • R5 and R5' are independently selected from halogen, -R51, -OR51, -NO2, - NR51R51', -NR 5i C(0)R 5r , -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 -r, - NR 5i C(0)NR 5i R 5i” , - SR51 , -S(0)R5i, -S(0)2R5i, -CN, haloalkyl, haloalkoxy, -C(0)0Rsi, -
  • R51, Rsr and Rsr are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl;
  • R 6 is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R7;
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl;
  • R 3 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted alkylcycloalkyl;
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl;
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -NO 2 , - NR 4i R 4 r, -NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 rR 4 -r, -SR 4 I , -S(0)R 4 I , -S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , - C(0)NR 4i R 4 r, -0CH 2 CH 2 0R 4 I , -NR 4i S(0) 2 NR 4 R 4i” and -C(CH 3 ) 2 0R 4 I ; wherein R 4 I , R 4 r and R 4 r are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound of general Formula (l a ’)
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -;
  • R a is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl;
  • R b is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R a and R b , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl;
  • R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; p is 0, 1 , 2, 3, 4 or 5; q is 0, 1 , 2, 3, 4 or 5;
  • n 0 or 1 ;
  • Ri is wherein m is 0, 1 or 2; r is 0, 1 or 2;
  • R5 and R5' are independently selected from halogen, -R51, -OR51, -NO2, - NR51R51', -NR 5i C(0)R 5r , -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 -r, - NR 5i C(0)NR 5i R 5i” , - SR51 , -S(0)R5i, -S(0)2R5i, -CN, haloalkyl, haloalkoxy, -C(0)0Rsi, - C(0)NR 5i R 5 r, -OCH 2 CH 2 OR 5I , -NR 5i S(0) 2 NR 5 rR 5i and -C(CH 3 ) 2 OR 5I ; wherein R51, Rsr and Rsr are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsub
  • R 6 is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R7; wherein the alkyl, alkenyl or alkynyl defined in R 6 , if substituted, is substituted with one or more substituent/s selected from -OR61, halogen, -CN, haloalkyl, haloalkoxy and -NReiRer; wherein the cycloalkyl, aryl and heterocyclyl defined in
  • OCH2CH2OR61 OCH2CH2OR61, -NR6iS(0) 2 NR 6 rR6r' and -C(CH3)20R6i; preferably selected from halogen, -R 61 , -OR 61 , -NR 6i R 6 r, -CN, haloalkyl and haloalkoxy; wherein R 61 , Rer and R 6i” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl;
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl; wherein the alkyl, alkenyl or alkynyl defined in R 7 , if substituted, is substituted with one or more substituent/s selected from -OR 71 , halogen, -CN, haloalkyl, haloalkoxy and -NR71R71'; wherein the cycloalkyl, aryl and heterocyclyl, as defined in R 7 ,
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; wherein, the alkyl, alkenyl or alkynyl defined in R 3' , if substituted, is substituted with one or more substituent/s selected from -OR 32 , halogen, -CN, haloalkyl, haloalkoxy and -NR32R32'; wherein R 32 and R 32' are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl;
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -NO 2 , - NR 4i R 4 r, -NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 rR 4 -r, -SR 4 I , -S(0)R 4 I , -S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , -
  • R 4 I , R 4 r and R 4 r are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl and substituted or unsubstituted cycloalkyl;
  • Rg and Rg ⁇ are independently selected from halogen, -R 21 , -OR 21 , -NO 2 , - NR21R21’, -NR 2i C(0)R 2 r, -NR2iS(0)2R2 , -S(0)2NR2iR2 , - NR2iC(0)NR2i R2i”, -SR21 , -S(0)R2i, -S(0)2R2i, -CN, haloalkyl, haloalkoxy, -C(0)0R2i, - C(0)NR 2i R 2 r, -OCH2CH2OR21, -NR2iS(0) 2 NR 2 rR2r' and -C(CH 3 ) 2 OR 2 I ; wherein R 21 , R 21' and R 21” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsub
  • the compound according to the invention of general Formula (I) is a compound of general Formula (l b )
  • Ri, R3, R3', R 4 , R 4 ⁇ , R9, RET, X, Ui, Y2 and n are as defined below in the detailed description, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound of general Formula (l b )
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -;
  • R a is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl;
  • R b is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R a and R b , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl;
  • R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; p is 0, 1 , 2, 3, 4 or 5; q is 0, 1 , 2, 3, 4 or 5; n is 0 or 1 ;
  • Yi is -C(RioRio')-; wherein R 10 and Rio ⁇ are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10 and R-io form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl;
  • Y2 is -C(Rio”Rio )-! wherein Rio- and R 10 - are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10” and Rio- form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl;
  • R5 and R5' are independently selected from halogen, -R51, -OR51, -NO2, - NR51R51', -NR 5i C(0)R 5r , -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 -r, - NR 5i C(0)NR 5i R 5i” , - SR51 , -S(0)R5i, -S(0)2R5i, -CN, haloalkyl, haloalkoxy, -C(0)0Rsi, - C(0)NR 5i R 5 r, -OCH 2 CH 2 OR 5 I , -NR 5i S(0) 2 NR 5 rR 5i and -C(CH 3 ) 2 OR 5 I ; wherein R51, Rsr and R 5 r are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or
  • R 6 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R7;
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl;
  • R 3 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted alkylcycloalkyl;
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl;
  • R 4 and R 4 ⁇ are independently selected from halogen, -R 4 I , -OR 4 I , -NO2, -
  • Rg and Rg ⁇ are independently selected from halogen, -R21, -OR21, -NO2, - NR21R21', -NR 2i C(0)R 2 r, -NR 2i S(0) 2 R2r, -S(0) 2 NR 2i R2r, - NR 2i C(0)NR 2 rR2r,
  • R 21 , R 21' and R 21” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -;
  • R a is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl
  • R b is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R a and R b , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl
  • R z is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstit
  • n 0 or 1 ;
  • Yi is -C(RioRio')-; wherein R 10 and Rio ⁇ are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10 and Re form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl;
  • Y 2 is -C(Rio”Rio )-; wherein Rio- and R-io- are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10” and Rio- form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl;
  • R5 and R5' are independently selected from halogen, -R51, -OR51, -NO2, - NR51R51', -NR 5i C(0)R 5r , -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 -r, - NR 5i C(0)NR 5i R 5i” , - SR51 , -S(0)R5i, -S(0)2R5i, -CN, haloalkyl, haloalkoxy, -C(0)0Rsi, -
  • R51, Rsr and Rsr are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl;
  • R 6 is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R7; wherein the alkyl, alkenyl or alkynyl defined in R 6 , if substituted, is substituted with one or more substituent/s selected from -OR 61 , halogen, -CN, haloalkyl, haloalkoxy and -NRei Rer; wherein the cycloalkyl, aryl and heterocyclyl
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl; wherein the alkyl, alkenyl or alkynyl defined in R 7 , if substituted, is substituted with one or more substituent/s selected from -OR 71 , halogen, -CN, haloalkyl, haloalkoxy and -NR71R71'; wherein the cycloalkyl, aryl and heterocyclyl, as defined in R 7 ,
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; wherein, the alkyl, alkenyl or alkynyl defined in R 3' , if substituted, is substituted with one or more substituent/s selected from -OR32, halogen, -CN, haloalkyl, haloalkoxy and -NR32R32'; wherein R32 and R32' are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl;
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -NO2, - NR 4i R 4 r, -NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 rR 4 -r, -SR 4 I , -S(0)R 4 I , -S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , - C(0)NR 4i R 4 r, -0CH 2 CH 2 0R 4 I , -NR 4i S(0) 2 NR 4 R 4i” and -C(CH 3 ) 2 0R 4 I ; wherein R 4 I , R 4 r and R 4 r are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubsti
  • Rg and Rg ⁇ are independently selected from halogen, -R21, -OR21, -NO2, - NR21R21’, -NR 2i C(0)R 2 r, -NR2iS(0)2R2 , -S(0)2NR2iR2 , - NR2iC(0)NR2i R2i”, -SR21 , -S(0)R2i, -S(0)2R2i, -CN, haloalkyl, haloalkoxy, -C(0)0R2i, - C(0)NR 2i R 2 r, -OCH2CH2OR21, -NR2iS(0) 2 NR 2 rR2r' and -C(CH 3 ) 2 OR 2 I ; wherein R 21 , R 21' and R 21” are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C
  • R 14 , Ru ⁇ and R-u- are independently selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl;
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound of general Formula (l b ’)
  • Ri, R3, R3', R 4 , R 4 ⁇ , R9, R9', X and n are as defined below in the detailed description, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound of general Formula (l b ’)
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -;
  • R a is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl;
  • R b is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R a and R b , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl;
  • R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; p is 0, 1 , 2, 3, 4 or 5; q is 0, 1 , 2, 3, 4 or 5; n is 0 or 1 ;
  • R5 and Rs ⁇ are independently selected from halogen, -R51, -OR51, -NO2, -
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl;
  • R 3 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted alkylcycloalkyl;
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl;
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -NO2, - NR 4i R 4 r, -NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 rR 4 -r, -SR 4 I , -S(0)R 4 I , -S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , - C(0)NR 4i R 4 r, -0CH 2 CH 2 0R 4 I , -NR 4i S(0) 2 NR 4 R 4i” and -C(CH 3 ) 2 0R 4 I ; wherein R 41 , R 4 r and R 41” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstit
  • Rg and Rg ⁇ are independently selected from halogen, -R 21 , -OR 21 , -NO 2 , - NR21R21’, -NR 2i C(0)R 2 r, -NR2iS(0)2R2 , -S(0)2NR2iR2 , - NR2iC(0)NR2i R2i”, -SR21 , -S(0)R2i, -S(0)2R2i, -CN, haloalkyl, haloalkoxy, -C(0)0R2i, - C(0)NR 2i R 2 r, -OCH2CH2OR21, -NR2iS(0) 2 NR 2 rR2r' and -C(CH 3 ) 2 OR 2 I ; wherein R 21 , R 21' and R 21” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsub
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound of general Formula (l b ’)
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -;
  • R a is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl;
  • R b is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R a and R b , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl;
  • R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; p is 0, 1 , 2, 3, 4 or 5; q is 0, 1 , 2, 3, 4 or 5; n is 0 or 1 ;
  • R5 and Rs ⁇ are independently selected from halogen, -R51, -OR51, -NO2, -
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl; wherein the alkyl, alkenyl or alkynyl defined in R 7 , if substituted, is substituted with one or more substituent/s selected from -OR 71 , halogen, -CN, haloalkyl, haloalkoxy and -NR71R71'; wherein the cycloalkyl, aryl and heterocyclyl, as defined in R 7 ,
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; wherein, the alkyl, alkenyl or alkynyl defined in R 3' , if substituted, is substituted with one or more substituent/s selected from -OR 32 , halogen, -CN, haloalkyl, haloalkoxy and -NR32R32'; wherein R 32 and R 32' are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl;
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -NO 2 , - NR 4i R 4 r, -NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 rR 4 -r, -SR 4 I , -S(0)R 4 I , -S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , - C(0)NR 4i R 4 r, -0CH 2 CH 2 0R 4 I , -NR 4i S(0) 2 NR 4 R 4i” and -C(CH 3 ) 2 0R 4 I ; wherein R 4 I , R 4 r and R 4 r are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or
  • Rg and Rg ⁇ are independently selected from halogen, -R 21 , -OR 21 , -NO 2 , - NR21R21’, -NR 2i C(0)R 2 r, -NR2iS(0)2R2 , -S(0)2NR2iR2 , - NR2iC(0)NR2i R2i”, -SR21 , -S(0)R2i, -S(0)2R2i, -CN, haloalkyl, haloalkoxy, -C(0)0R2i, - C(0)NR 2i R 2 r, -OCH2CH2OR21, -NR2iS(0) 2 NR 2 rR2r' and -C(CH 3 ) 2 OR 2I ; wherein R 21 , R 21' and R 21” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsub
  • Ri, R3, R3', R 4 , R 4 ⁇ , R9, RET, X, Ui, Y2 and n are as defined below in the detailed description, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound of general Formula (l c ) wherein
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ]pC(0)N(Rz)[CH 2 ] q -, - [CH 2 ]pN(Rz)C(0)[CH 2 ] q - and -[CH 2 ]pN(Rz)[CH 2 ] q -;
  • R a is selected from hydrogen, halogen, substituted or unsubstituted C alkyl, substituted or unsubstituted C2- 6 alkenyl and substituted or unsubstituted C2- 6 alkynyl;
  • R b is selected from hydrogen, halogen, substituted or unsubstituted C1- 6 alkyl, substituted or unsubstituted C2- 6 alkenyl and substituted or unsubstituted C2- 6 alkynyl; alternatively, R a and R t> , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl;
  • R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C2- 6 alkenyl, substituted or unsubstituted C2- 6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; p is 0, 1 , 2, 3, 4 or 5; q is 0, 1 , 2, 3, 4 or 5; n is 0 or 1 ;
  • Yi is -C(RioRio')-; wherein R 10 and Rio ⁇ are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10 and R-io form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl;
  • Y2 is -C(Rio”Rio )-! wherein Rio- and R 10 - are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10” and Rio- form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl;
  • R5 and R5' are independently selected from halogen, -R51, -OR51, -NO2, - NR51R51', -NR 5i C(0)R 5r , -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 -r, - NR 5i C(0)NR 5i R 5i” , - SR51 , -S(0)R5i, -S(0)2R5i, -CN, haloalkyl, haloalkoxy, -C(0)0Rsi, - C(0)NR 5i R 5 r, -OCH 2 CH 2 OR 5 I , -NR 5i S(0) 2 NR 5 rR 5i and -C(CH 3 ) 2 OR 5 I ; wherein R51, Rsr and R 5 r are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or
  • R 6 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R7;
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl;
  • R 3 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted alkylcycloalkyl;
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl;
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -NO 2 , - NR 4i R 4 r, -NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 rR 4 -r, -SR 4 I , -S(0)R 4 I , -S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , -
  • R 4 I , R 4 r and R 4 r are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl and substituted or unsubstituted cycloalkyl;
  • Rg and Rg ⁇ are independently selected from halogen, -R 21 , -OR 21 , -NO 2 , - NR21R21’, -NR 2i C(0)R 2 r, -NR2iS(0)2R2 , -S(0)2NR2iR2 , - NR2iC(0)NR2i R2i”, -SR21 , -S(0)R2i, -S(0)2R2i, -CN, haloalkyl, haloalkoxy, -C(0)0R2i, - C(0)NR 2i R 2 r, -OCH2CH2OR21, -NR2iS(0) 2 NR 2 rR2r' and -C(CH 3 ) 2 OR 2 I ; wherein R 21 , R 21' and R 21” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsub
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -;
  • R a is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl;
  • R b is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R a and R b , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl;
  • R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; p is 0, 1 , 2, 3, 4 or 5; q is 0, 1 , 2, 3, 4 or 5;
  • n 0 or 1 ;
  • Yi is -C(RioRio')-; wherein R 10 and Rio ⁇ are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10 and Re form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl;
  • Y 2 is -C(Rio”Rio )-; wherein Rio- and R-io- are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10” and Rio- form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl;
  • R5 and R5' are independently selected from halogen, -R51, -OR51, -NO2, - NR51R51', -NR 5i C(0)R 5r , -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 -r, - NR 5i C(0)NR 5i R 5i” , - SR51 , -S(0)R5i, -S(0)2R5i, -CN, haloalkyl, haloalkoxy, -C(0)0Rsi, -
  • R51, Rsr and Rsr are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl;
  • R 6 is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R7; wherein the alkyl, alkenyl or alkynyl defined in R 6 , if substituted, is substituted with one or more substituent/s selected from -OR 61 , halogen, -CN, haloalkyl, haloalkoxy and -NRei Rer; wherein the cycloalkyl, aryl and heterocyclyl
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl; wherein the alkyl, alkenyl or alkynyl defined in R 7 , if substituted, is substituted with one or more substituent/s selected from -OR 71 , halogen, -CN, haloalkyl, haloalkoxy and -NR71R71'; wherein the cycloalkyl, aryl and heterocyclyl, as defined in R 7 ,
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; wherein, the alkyl, alkenyl or alkynyl defined in R 3' , if substituted, is substituted with one or more substituent/s selected from -OR32, halogen, -CN, haloalkyl, haloalkoxy and -NR32R32'; wherein R32 and R32' are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl;
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -NO2, - NR 4i R 4 r, -NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 rR 4 -r, -SR 4 I , -S(0)R 4 I , -S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , - C(0)NR 4i R 4 r, -0CH 2 CH 2 0R 4 I , -NR 4i S(0) 2 NR 4 R 4i” and -C(CH 3 ) 2 0R 4 I ; wherein R 4 I , R 4 r and R 4 r are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubsti
  • Rg and Rg ⁇ are independently selected from halogen, -R21, -OR21, -NO2, - NR21R21’, -NR 2i C(0)R 2 r, -NR2iS(0)2R2 , -S(0)2NR2iR2 , - NR2iC(0)NR2i R2i”,
  • R 21 , R 21' and R 21” are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl;
  • R 14 , Ru ⁇ and R-u- are independently selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl;
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound of general Formula (l c ’)
  • Ri, R3, R3', R 4 , R 4 ⁇ , R9, R9', X and n are as defined below in the detailed description, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound of general Formula (l c ’)
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -;
  • R a is selected from hydrogen, halogen, substituted or unsubstituted C alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl;
  • R b is selected from hydrogen, halogen, substituted or unsubstituted C alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R a and R b , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl;
  • R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; p is 0, 1 , 2, 3, 4 or 5; q is 0, 1 , 2, 3, 4 or 5;
  • n 0 or 1 ;
  • R5 and R5' are independently selected from halogen, -R51, -OR51, -NO2, - NR51R51', -NR 5i C(0)R 5r , -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 -r, - NR 5i C(0)NR 5i R 5i” , - SR51 , -S(0)R5i, -S(0)2R5i, -CN, haloalkyl, haloalkoxy, -C(0)0Rsi, -
  • R51, Rsr and Rsr are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl;
  • R 6 is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R7;
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl;
  • R 3 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted alkylcycloalkyl;
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl;
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -NO 2 , - NR 4i R 4 r, -NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 rR 4 -r, -SR 4 I , -S(0)R 4 I , -S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , - C(0)NR 4i R 4 r, -0CH 2 CH 2 0R 4 I , -NR 4i S(0) 2 NR 4 R 4i” and -C(CH 3 ) 2 0R 4 I ; wherein R 4 I , R 4 r and R 4 r are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound of general Formula (l c ’)
  • R a is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl;
  • R b is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R a and R b , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl;
  • R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; p is 0, 1 , 2, 3, 4 or 5; q is 0, 1 , 2, 3, 4 or 5;
  • n 0 or 1 ;
  • Ri is wherein m is 0, 1 or 2; r is 0, 1 or 2;
  • R5 and R5' are independently selected from halogen, -R51, -OR51, -NO2, - NR51R51', -NR 5i C(0)R 5r , -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 -r, - NR 5i C(0)NR 5i R 5i” , - SR51 , -S(0)R5i, -S(0)2R5i, -CN, haloalkyl, haloalkoxy, -C(0)0Rsi, - C(0)NR 5i R 5 r, -OCH 2 CH 2 OR 5I , -NR 5i S(0) 2 NR 5 rR 5i and -C(CH 3 ) 2 OR 5I ; wherein R51, Rsr and Rsr are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsub
  • R 6 is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R7; wherein the alkyl, alkenyl or alkynyl defined in R 6 , if substituted, is substituted with one or more substituent/s selected from -OR61, halogen, -CN, haloalkyl, haloalkoxy and -NReiRer; wherein the cycloalkyl, aryl and heterocyclyl defined in
  • OCH2CH2OR61 OCH2CH2OR61, -NR6iS(0) 2 NR 6 rR6r' and -C(CH3)20R6i; preferably selected from halogen, -R 61 , -OR 61 , -NR 6i R 6 r, -CN, haloalkyl and haloalkoxy; wherein R 61 , Rer and R 6i” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl;
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl; wherein the alkyl, alkenyl or alkynyl defined in R 7 , if substituted, is substituted with one or more substituent/s selected from -OR 71 , halogen, -CN, haloalkyl, haloalkoxy and -NR71R71'; wherein the cycloalkyl, aryl and heterocyclyl, as defined in R 7 ,
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; wherein, the alkyl, alkenyl or alkynyl defined in R 3 ⁇ , if substituted, is substituted with one or more substituent/s selected from -OR 32 , halogen, -CN, haloalkyl, haloalkoxy and -NR 32 R 32' ; wherein R 32 and R 32 ⁇ are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl;
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -NO 2 , - NR 4i R 4 r, -NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 rR 4 -r, -SR 4 I , -S(0)R 4 I , -S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , -
  • R 4 I , R 4 r and R 4 r are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl and substituted or unsubstituted cycloalkyl;
  • Rg and Rg ⁇ are independently selected from halogen, -R 21 , -OR 21 , -NO 2 , - NR21R21’, -NR 2i C(0)R 2 r, -NR2iS(0)2R2 , -S(0)2NR2iR2 , - NR2iC(0)NR2i R2i”, -SR21 , -S(0)R2i, -S(0)2R2i, -CN, haloalkyl, haloalkoxy, -C(0)0R2i, - C(0)NR 2i R 2 r, -OCH2CH2OR21, -NR2iS(0) 2 NR 2 rR2r and -C(CH 3 ) 2 OR 2 I ; wherein R 21 , R 21' and R 21” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubsti
  • R-u, Ru ⁇ and Ru ⁇ are independently selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • n means the number of times that -CH2- is repeated. The same would apply, when applicable, to general Markush Formulae (G), (l a ), (l a ), (l b ), (l b ), (l c ) and (l c ), and to all intermediates of synthesis.
  • This definition is also generally applicable and can be also applied as a definition of any other cycle (preferably cycloalkyls, heterocycls or aryls) formed from two different functional groups like e.g.“the cycle in Ri-Ri“ means the cycle resulting when R, and R, ⁇ form a cycle together with the atom(s) to which they are attached. This cycle can then be substituted or not.
  • alkyl is understood as meaning saturated, linear or branched hydrocarbons, which may be unsubstituted or substituted once or several times. It encompasses e.g. -CH3 and -CH2-CH3.
  • Ci-2-alkyl represents C1- or C2-alkyl
  • Ci-3-alkyl represents C1-, C2- or C3-alkyl
  • Ci- 4 -alkyl represents C1-, C2-, C3- or C4-alkyl
  • Ci-5-alkyl represents C1-, C2-, C3-, C4-, or 05- alkyl
  • Ci-6-alkyl represents C1-, C2-, C3-, C4-, C5- or C6-alkyl
  • Ci-7-alkyl represents C1-, C2-, C3-, C4-, C5-, C6- or C7-alkyl
  • Ci-s-alkyl represents C1-, C2-, C3-, C4-,
  • Ci-10-alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9- or C10-alkyl and Ci-is-alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9-, C10-, C11-, C12-, C13-, C14-, C15-, C16-, C17- or C18-alkyl.
  • the alkyl radicals are preferably methyl, ethyl, propyl, methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1 ,1-dimethylethyl, pentyl, 1 ,1-dimethylpropyl, 1 ,2-dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1-methylpentyl, if substituted also CHF2, CF3 or CH2OH etc.
  • alkyl is understood in the context of this invention as Ci-salkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl; preferably is Ci- 6 alkyl like methyl, ethyl, propyl, butyl, pentyl, or hexyl; more preferably is Ci- 4 alkyl like methyl, ethyl, propyl or butyl.
  • alkenyl radicals are preferably vinyl (ethenyl), allyl (2-propenyl).
  • alkenyl is C 2 -io-alkenyl or C 2-8 - alkenyl like ethylene, propylene, butylene, pentylene, hexylene, heptylene or octylene; or is C 2-6 -alkenyl like ethylene, propylene, butylene, pentylene, or hexylene; or is C 2-4 -alkenyl, like ethylene, propylene, or butylenes.
  • Alkynyl is understood as meaning unsaturated, linear or branched hydrocarbons, which may be unsubstituted or substituted once or several times. It encompasses groups like e.g. -C ⁇ C-CHs (1-propinyl).
  • alkynyl in the context of this invention is C 2 -io-alkynyl or C 2-8 -alkynyl like ethyne, propyne, butyene, pentyne, hexyne, heptyne, or octyne; or is C 2-6 -alkynyl like ethyne, propyne, butyene, pentyne, or hexyne; or is C 24 -alkynyl like ethyne, propyne, butyene, pentyne, or hexyne.
  • alkyl also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl
  • substituted in the context of this invention is understood as meaning replacement of at least one hydrogen radical on a carbon atom by halogen (F, Cl, Br, I), -NRkRk ⁇ , -SRk, -S(0)Rk, -S(0)2Rk, -ORk, - C(0)Rk, -C(0)ORk, -CN, -C(0)NRkRk ⁇ haloalkyl, haloalkoxy, being Rk represented by Ri3, R31 , R32, R61 or R71 (being Rk ⁇ represented by R13', R31 ', R32', Rer or R 7 r ; being Rk- represented by R13”, R31”, R32 ', Rer or R71 ); wherein R1 to R 7 r and R
  • alkyl also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl
  • alkenyl, alkynyl or O-alkyl substituted is understood in the context of this invention that any alkyl (also in alkylaryl, alkylheterocyclyl or alkylcycloalkyl), alkenyl, alkynyl or O-alkyl which is substituted with one or more of halogen (F, Cl, Br, I), -NRkRk ⁇ , -ORk, -CN, -SRk, haloalkyl, haloalkoxy, being Rk represented by R13, R31 , R32, R61 or R 7 I , (being Rk ⁇ represented by R13', R31 ', R32', Rer or R 7 r ; being Rk- represented by R13 ", R31 ", R32 ", Rer ⁇ or R 7 r) ; wherein R1 to R
  • More than one replacement on the same molecule and also on the same carbon atom is possible with the same or different substituents.
  • This includes for example 3 hydrogens being replaced on the same C atom, as in the case of CF 3 , or at different places of the same molecule, as in the case of e.g. -CH(OH)-CH CH-CHCl2.
  • haloalkyl is understood as meaning an alkyl being substituted once or several times by a halogen (selected from F, Cl, Br, I). It encompasses e.g. -CH2CI, -CH2F, -CHC , -CHF2, -CCI3, -CF3 and -CH2-CHCI2.
  • haloalkyl is understood in the context of this invention as halogen- substituted Ci-4-alkyl representing halogen substituted C1-, C2-, C3- or C4-alkyl.
  • the halogen-substituted alkyl radicals are thus preferably methyl, ethyl, propyl, and butyl.
  • Preferred examples include -CH 2 CI, -CH 2 F, -CHCb, -CHF 2 , and -CF 3 .
  • haloalkoxy is understood as meaning an -O-alkyl being substituted once or several times by a halogen (selected from F, Cl, Br, I). It encompasses e.g. -OCH2CI, -OCH2F, -OCHC , -OCHF2, -OCCI3, -OCF3 and - OCH2-CHCI2.
  • haloalkoxy is understood in the context of this invention as halogen-substituted -OCi-4-alkyl representing halogen substituted C1-, C2-, C3- or C4-alkoxy.
  • the halogen-substituted alkyl radicals are thus preferably O-methyl, O- ethyl, O-propyl, and O-butyl.
  • Preferred examples include -OCH2CI, -OCH2F, - OCHC , -OCHF2, and -OCF3.
  • cycloalkyl is understood as meaning saturated and unsaturated (but not aromatic) cyclic hydrocarbons (without a heteroatom in the ring), which can be unsubstituted or once or several times substituted.
  • C3-4- cycloalkyl represents C3- or C4-cycloalkyl
  • C3-5-cycloalkyl represents C3-, C4- or C5- cycloalkyl
  • C3-6-cycloalkyl represents C3-, C4-, C5- or C6-cycloalkyl
  • C3-7-cycloalkyl represents C3-, C4-, C5-, C6- or C7-cycloalkyl
  • C3-8-cycloalkyl represents C3-, C4-, C5-, C6-, C7- or C8-cycloalkyl
  • C4-5-cycloalkyl represents C4- or C5-cycloalkyl
  • C4-6- cycloalkyl represents C4-, C
  • Examples are cyclopropyl, 2- methylcyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cycloheptyl, cyclooctyl, and also adamantyl.
  • cycloalkyl is C3-8cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; or is C3-7cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; or is C3-6cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, especially cyclopentyl or cyclohexyl.
  • Aryl is understood as meaning 5 to 18 membered mono or polycyclic ring systems with at least one aromatic ring but without heteroatoms even in only one of the rings. Examples are phenyl, naphthyl, fluoranthenyl, fluorenyl, tetralinyl or indanyl, 9H- fluorenyl or anthracenyl radicals, which can be unsubstituted or once or several times substituted. Most preferably aryl is understood in the context of this invention as phenyl, naphthyl or anthracenyl, preferably is phenyl.
  • a heterocyclyl radical or group (also called heterocyclyl hereinafter) is understood as meaning 5 to 18 membered mono or polycyclic heterocyclic ring systems, with at least one saturated or unsaturated ring which contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring.
  • a heterocyclic group can also be substituted once or several times.
  • Subgroups inside the heterocyclyls as understood herein include heteroaryls and non-aromatic heterocyclyls.
  • the heteroaryl (being equivalent to heteroaromatic radicals or aromatic heterocyclyls) is an aromatic 5 to 18 membered mono or polycyclic heterocyclic ring system of one or more rings of which at least one aromatic ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a 5 to 18 membered mono or polycyclic aromatic heterocyclic ring system of one or two rings of which at least one aromatic ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, pyrimidine, pyrazine, quinoline, isoquinoline, phthalazine, benzothiazole, indole, benzotriazole, carbazole, quinazoline, thiazole, imidazole, pyrazole, oxazole, thi
  • the non-aromatic heterocyclyl is a 5 to 18 membered mono or polycyclic heterocyclic ring system of one or more rings of which at least one ring - with this (or these) ring(s) then not being aromatic - contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a 5 to 18 membered mono or polycyclic heterocyclic ring system of one or two rings of which one or both rings - with this one or two rings then not being aromatic - contain/s one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from oxazepam, pyrrolidine, piperidine, piperazine, tetrahydropyran, morpholine, indoline, oxopyrrolidine, benzodioxane, especially is benzodioxane, morpholine, tetrahydropyran, piperidine,
  • heterocyclyl is defined as a 5 to 18 membered mono or polycyclic heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring.
  • it is a 5 to 18 membered mono or polycyclic heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring.
  • heterocyclyls include oxazepan, pyrrolidine, imidazole, oxadiazole, tetrazole, pyridine, pyrimidine, piperidine, piperazine, , benzofuran, benzimidazole, indazole, benzodiazole, thiazole, benzothiazole, tetrahydropyrane, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene, benzothiophene, pyrrole, pyrazine, pyrrolo[2,3b]pyridine, quinoline, isoquinoline, tetrahydroisoquinoline, phthalazine, benzo-1 ,2,5-thiadiazole, indole, benzotriazole, benzoxazole oxopyrrolidine, pyrimidine, benzodioxolane, benzodioxane, carb
  • oxopyrrolidine is understood as meaning pyrrolidin-2- one.
  • An /V-containing heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains a nitrogen and optionally one or more further heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains a nitrogen and optionally one or more further heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from oxazepam, pyrrolidine, imidazole, oxadiazole, tetrazole, azetidine, pyridine, pyrimidine, piperidine, piperazine, benzimidazole, indazole, benzothiazole, benzodiazole, morpholine, indoline, triazole, isoxazole, pyrazole, pyrrole, pyrazine, pyrrol
  • a cyclic amide is defined as a subgroup of a heterocyclyl (as defined above) formed through the cyclization of a carbon sequence, containing at least the sequence
  • Said cyclic amide may optionally be fused to a ring system.
  • the cyclic amide is an“indoline-2-one”.
  • a cyclic amide may be substituted or unsubstituted as defined for heterocyclyl above.
  • a cyclic urea is defined as a subgroup of a heterocyclyl (as defined above) formed through the cyclization of a carbon sequence containing at least the sequence
  • Said cyclic urea may optionally be fused to a ring system.
  • the cyclic urea is“1 H-benzo[d]imidazol-2(3H)-one”.
  • a cyclic urea may be substituted or unsubstituted as defined for heterocyclyl above.
  • the ring system is defined first as an aromatic heterocyclyl (heteroaryl) if at least one aromatic ring contains a heteroatom. If no aromatic ring contains a heteroatom, then the ring system is defined as a non- aromatic heterocyclyl if at least one non-aromatic ring contains a heteroatom. If no non-aromatic ring contains a heteroatom, then the ring system is defined as an aryl if it contains at least one aryl cycle.
  • alkylaryl is understood as meaning an aryl group (see above) being connected to another atom through a Ci- 6 -alkyl (see above) which may be branched or linear and is unsubstituted or substituted once or several times.
  • alkylaryl is understood as meaning an aryl group (see above) being connected to another atom through 1 to 4 (-CH2-) groups.
  • alkylaryl is benzyl (i.e. -Chh-phenyl).
  • alkylheterocyclyl is understood as meaning an heterocyclyl group being connected to another atom through a Ci- 6 -alkyl (see above) which may be branched or linear and is unsubstituted or substituted once or several times.
  • alkylheterocyclyl is understood as meaning an heterocyclyl group (see above) being connected to another atom through 1 to 4 (-CH2-) groups.
  • alkylheterocyclyl is -Chh-pyridine.
  • alkylcycloalkyl is understood as meaning an cycloalkyl group being connected to another atom through a Ci- 6 -alkyl (see above) which may be branched or linear and is unsubstituted or substituted once or several times.
  • alkylcycloalkyl is understood as meaning a cycloalkyl group (see above) being connected to another atom through 1 to 4 (-CH2-) groups.
  • alkylcycloalkyl is -Chh-cyclopropyl.
  • An heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from oxazepan, pyrrolidine, imidazole, oxadiazole, tetrazole, azetidine, pyridine, pyrimidine, piperidine, piperazine, benzofuran, benzimidazole, indazole, benzothiazole, benzodiazole, thiazole, benzothiazole, tetrahydropyran, morpholine, indoline, furan, triazole, isoxazole, pyrazole, thiophene,
  • a heterocyclyl may contain between 3 and 12 atoms in the ring (preferably 4 to 10 atoms in the ring, or 5 to 8 atoms in the ring, or 5 to 6 atoms in the ring) in case of a heterocyclyl of one saturated or unsaturated ring.
  • Such a heterocyclyl may also contain between 5 and 22 atoms in both rings together (preferably 6 to 16 atoms in both rings together, or 7 to 12 atoms in both rings together or 8 to 10 atoms in both rings together) in case of a heterocyclyl of two saturated or unsaturated rings.
  • Such a heterocyclyl may also contain between 7 and 32 atoms in the 3 rings together (preferably 10 to 22 atoms in the three rings together, or 12 to 20 atoms in the three rings together or 10 to 18 atoms in the three rings together) in case of a heterocyclyl of three saturated or unsaturated rings.
  • the aryl is a monocyclic aryl. More preferably the aryl is a 5, 6 or 7 membered monocyclic aryl. Even more preferably the aryl is a 5 or 6 membered monocyclic aryl.
  • the heteroaryl is a monocyclic heteroaryl. More preferably the heteroaryl is a 5, 6 or 7 membered monocyclic heteroaryl. Even more preferably the heteroaryl is a 5 or 6 membered monocyclic heteroaryl.
  • the non-aromatic heterocyclyl is a monocyclic non-aromatic heterocyclyl. More preferably the non-aromatic heterocyclyl is a 4, 5, 6 or 7 membered monocyclic non-aromatic heterocyclyl. Even more preferably the non-aromatic heterocyclyl is a 5 or 6 membered monocyclic non-aromatic heterocyclyl.
  • the cycloalkyl is a monocyclic cycloalkyl. More preferably the cycloalkyl is a 3, 4, 5, 6, 7 or 8 membered monocyclic cycloalkyl. Even more preferably the cycloalkyl is a 3, 4, 5 or 6 membered monocyclic cycloalkyl.
  • aryl including alkyl-aryl
  • cycloalkyl including alkyl-cycloalkyl
  • heterocyclyl including alkyl-heterocyclyl
  • aryl including alkyl-aryl
  • cycloalkyl including alkyl-cycloalkyl
  • heterocyclyl including alkyl-heterocyclyl
  • any aryl, cycloalkyl and heterocyclyl which is substituted is substituted (also in an alyklaryl, alkylcycloalkyl or alkylheterocyclyl) with one or more of halogen (F, Cl, Br, I), -R k ,-OR k , -CN , -N0 2 , - NRkRk” , NRkC(0)R k' , -NR k S(0) 2 R k' , -S(0) 2 NR k R k' , -NR k C(0)NR k Rk", haloalkyl, haloalkoxy, -SR k , -S(0)R k or S(0) 2 R
  • cycloalkyl including alkyl-cycloalkyl
  • heterocyclyl including alkylheterocyclyl
  • non-aromatic heterocyclyl including non-aromatic alkyl- heterocyclyl
  • cycloalkyl including alkyl-cycloalkyl
  • heterocyclyl including alkylheterocyclyl
  • non-aromatic heterocyclyl including non- aromatic alkyl-heterocyclyl
  • cycloalkyl including alkyl-cycloalkyl
  • heterocyclyl including alkylheterocyclyl
  • non-aromatic heterocyclyl including non- aromatic alkyl-heterocyclyl
  • R a , R b and p are as defined in the description.
  • X can also be expressed as:
  • R a , R b and p are as defined in the description.
  • R a ⁇ and R b ⁇ are added.
  • this statement is thus reflected in that R a ⁇ and R b ⁇ are or could be different from R a and R b or not.
  • a ring system is a system consisting of at least one ring of connected atoms but including also systems in which two or more rings of connected atoms are joined with “joined” meaning that the respective rings are sharing one (like a spiro structure), two or more atoms being a member or members of both joined rings.
  • leaving group means a molecular fragment that departs with a pair of electrons in heterolytic bond cleavage.
  • Leaving groups can be anions or neutral molecules. Common anionic leaving groups are halides such as CI-, Br-, and I-, and sulfonate esters, such as tosylate (TsO-) or mesylate.
  • salt is to be understood as meaning any form of the active compound used according to the invention in which it assumes an ionic form or is charged and is coupled with a counter-ion (a cation or anion) or is in solution. By this are also to be understood complexes of the active compound with other molecules and ions, in particular complexes via ionic interactions.
  • physiologically acceptable salt means in the context of this invention any salt that is physiologically tolerated (most of the time meaning not being toxic- especially not caused by the counter-ion) if used appropriately for a treatment especially if used on or applied to humans and/or mammals.
  • physiologically acceptable salts can be formed with cations or bases and in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention - usually a (deprotonated) acid - as an anion with at least one, preferably inorganic, cation which is physiologically tolerated - especially if used on humans and/or mammals.
  • the salts of the alkali metals and alkaline earth metals are particularly preferred, and also those with NH 4 , but in particular (mono)- or (di)sodium, (mono)- or (di)potassium, magnesium or calcium salts.
  • Physiologically acceptable salts can also be formed with anions or acids and in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention as the cation with at least one anion which are physiologically tolerated - especially if used on humans and/or mammals.
  • the salt formed with a physiologically tolerated acid that is to say salts of the particular active compound with inorganic or organic acids which are physiologically tolerated - especially if used on humans and/or mammals.
  • physiologically tolerated salts of particular acids are salts of: hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid or citric acid.
  • the compounds of the invention may be present in crystalline form or in the form of free compounds like a free base or acid.
  • solvate any compound that is a solvate of a compound according to the invention like a compound according to general formula I defined above is understood to be also covered by the scope of the invention. Methods of solvation are generally known within the art. Suitable solvates are pharmaceutically acceptable solvates.
  • the term “solvate” according to this invention is to be understood as meaning any form of the active compound according to the invention in which this compound has attached to it via non-covalent binding another molecule (most likely a polar solvent). Especially preferred examples include hydrates and alcoholates, like methanolates or ethanolates.
  • prodrug is used in its broadest sense and encompasses those derivatives that are converted in vivo to the compounds of the invention. Such derivatives would readily occur to those skilled in the art, and include, depending on the functional groups present in the molecule and without limitation, the following derivatives of the present compounds: esters, amino acid esters, phosphate esters, metal salts sulfonate esters, carbamates, and amides. Examples of well known methods of producing a prodrug of a given acting compound are known to those skilled in the art and can be found e.g. in Krogsgaard-Larsen et al. “Textbook of Drug design and Discovery” Taylor & Francis (April 2002).
  • the compounds of the invention are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13 C- or 14 C-enriched carbon or of a nitrogen by 15 N-enriched nitrogen are within the scope of this invention. This would especially also apply to the provisos described above so that any mentioning of hydrogen or any ⁇ ” in a formula would also cover deuterium or tritium.
  • the compounds of formula (I) as well as their salts or solvates of the compounds are preferably in pharmaceutically acceptable or substantially pure form.
  • pharmaceutically acceptable form is meant, inter alia, having a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels.
  • Purity levels for the drug substance are preferably above 50%, more preferably above 70%, most preferably above 90%. In a preferred embodiment it is above 95% of the compound of formula (I), or of its salts. This applies also to its solvates or prodrugs.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -;
  • R a is selected from hydrogen, halogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl;
  • R b is selected from hydrogen, halogen, substituted or unsubstituted C alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R a and R b , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl;
  • R z is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein X is selected from a bond, -[C(R a R b )] P -, -[CH 2 ] p C(0)[CH 2 ] q - and
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R a is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein R a is selected from hydrogen, halogen and substituted or unsubstituted C 1-6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • R a is selected from hydrogen, halogen and substituted or unsubstituted C 1-6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R b is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R b is selected from hydrogen, halogen and substituted or unsubstituted C 1-6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R a and R b taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R z is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein R z is selected from hydrogen and substituted or unsubstituted Ci- 6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein p is 0, 1 , 2, 3, 4 or 5; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein q is 0, 1 , 2, 3, 4 or 5; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein n is 0 or 1 ; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein m is 0, 1 or 2; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein r is 0, 1 or 2; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • the compound according to the invention of general Formula (I) is a compound wherein
  • Yi is -C(RioRio')-; wherein R 10 and Rio ⁇ are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10 and R-io form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • Y2 is -C(Rio”Rio )-; wherein Rio- and R-io- are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; alternatively, R 10” and Rio- form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein Yi is -C(R-io io')-; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • Y 2 is -C(Rio”Rio )-; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R2 is selected from substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R2 is selected from substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 3 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted alkylcycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 3 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted alkylcycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein R3 is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted alkylcycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • R3 is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted alkylcycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R3 is substituted or unsubstituted C1-6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R3' is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein R3' is selected from hydrogen and substituted or unsubstituted C1-6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -NO2, -NR 4i R 4 r, - NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 -rR 4 -r, -SR 4 I , -S(0)R 4i , - S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , -C(0)NR 4i R 4 r, -OCFhCFhOR ⁇ , -
  • R 4 I , R 4 r and R 4 r are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl and substituted or unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 4 and R 4' are independently selected from halogen, -R 4I , -OR 4I , -NO2, -NR 4i R 4 r, - NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 -rR 4 -r, -SR 4I , -S(0)R 4i , - S(0) 2 R 4I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , -C(0)NR 4i R 4 r, -0CH 2 CH 2 0R 4I , - NR 4i S(0) 2 NR 4i ' R 4i” and -C(CH 3 ) 2 0R 4I ; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture
  • R 4 and R 4' are both -R 4I ; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 4 and R 4' are both hydrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R5 and R5' are independently selected from halogen, -R51, -OR51, -NO2, -NR51R51', - NR 5i C(0)R 5 r, -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 r, - NR 5i C(0)NR 5 rR 5 r, -SR 5 I , -S(0)R 5i , -S(0) 2 R5i, -CN, haloalkyl, haloalkoxy, -C(0)0Rsi, -C(0)NR 5i R5r, -OCH 2 CH 2 OR5i, - NR 5i S(0) 2 NR 5 rR 5 r and -C(CH3) 2 OR5i; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 5 and R 5' are independently selected from -R 51 and -OR 51 ,; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R5 is selected from -R51 and -OR51; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 5 is selected from hydrogen and -OH; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R5' is -R51; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • Re ⁇ is hydrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 6 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R ?
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 6 is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R ?
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 6 is selected from hydrogen and substituted or unsubstituted Ci- 6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R7 is selected from substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • Rg and Rg ⁇ are independently selected from halogen, -R21, -OR21, -NO2, -NR21R21', - NR 2i C(0)R 2 r, -NR 2i S(0) 2 R 2 r, -S(0) 2 NR 2i R2r, - NR 2i C(0)NR 2 rR2r, -SR21 , -S(0)R 21 , -S(0)2R2i, -CN, haloalkyl, haloalkoxy, -C(0)0R2i, -C(0)NR2iR2r, -OCH2CH2OR21, - NR 2i S(0) 2 NR 2 rR2i” and -C(CH3)20R2i; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastere
  • the compound according to the invention of general Formula (I) is a compound wherein
  • Rg and Rg ⁇ are independently selected from -R21 ; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • Rg and Rg ⁇ are both hydrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 10 and R 10’ are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl and substituted or unsubstituted C2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 10 and Rio ⁇ are independently selected from hydrogen and substituted or unsubstituted Ci-6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 10 and Re form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 10 and R 10 are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 10 and R 10 are independently selected from hydrogen and substituted or unsubstituted Ci-6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 13 and Ri 3' are independently selected from hydrogen, unsubstituted Ci-6 alkyl, unsubstituted C 2-6 alkenyl and unsubstituted C 2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R13 and Ri3' are independently selected from hydrogen and unsubstituted Ci- 6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R M , Ri4’ and R-u- are independently selected from hydrogen, unsubstituted Ci- 6 alkyl, unsubstituted C2-6 alkenyl, unsubstituted C2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R M , R M’ and R-u- are independently selected from hydrogen, unsubstituted C1-6 alkyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 21 , R 21' and R 21” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 21 , R 21' and R 21” are independently selected from hydrogen and substituted or unsubstituted C 1-6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein R 31 , R 31' and R 31 " are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 31 , R 31' and R 31 " are independently selected from hydrogen and substituted or unsubstituted C 1-6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein R 32 and R 32' are independently selected from hydrogen, substituted or unsubstituted
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 32 and R 32' are independently selected from hydrogen and substituted or unsubstituted C 1-6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 41 , R 41' and R 41” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl and substituted or unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 41 , R 41' and R 41” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl and substituted or unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 51 , R 51' and R 51 " are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 51 , R 51' and R 51 " are independently selected from hydrogen and substituted or unsubstituted C 1-6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 61 , R 61' and Rev are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 6i , R61' and Rev are independently selected from hydrogen and substituted or unsubstituted Ci- 6 alkyll; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein R71 , R71’ and R 7 r are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein R71 , R71’ and R 7 r are independently selected from hydrogen and substituted or unsubstituted C1-6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 2 is selected from substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl, wherein the aryl or heterocyclyl in R2, if substituted, is substituted with one or more substituent/s selected from halogen, -R21, -OR21, -NO2, -NR21R21', -NR2iC(0)R2r, - NR 2i S(0) 2 R2r, -S(0) 2 NR 2i R2r, - NR 2i C(0)NR 2 rR2r, -SR21 , -S(0)R 21 , -S(0) 2 R 21 , - CN, haloalkyl, haloalkoxy, -C(0)0R2i, -C(0)NR2iR2r, -OCH2CH2OR21, NR 2i S(0) 2 NR 2 rR2i” and -C(CH3)20R2i; wherein R21, R21' and R21
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 31 , R 31' and R 31” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl; wherein, the alkyl, alkenyl or alkynyl defined in R 3' , if substituted, is substituted with one or more substituent/s selected from -OR32, halogen, -CN, haloalkyl, haloalkoxy and -N R32R32'; wherein R32 and R32' are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers,
  • the compound according to the invention of general Formula (I) is a compound wherein R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl; wherein, the alkyl, alkenyl or alkynyl defined in R3', if substituted, is substituted with one or more substituent/s selected from -OR32, halogen, -CN, haloalkyl, haloalkoxy and -N R32R32'; wherein R32 and R32' are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers,
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 6 is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R ?
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 6 is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R ?
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R6 is selected from hydrogen and substituted or unsubstituted Ci-6 alkyl; wherein the alkyl, alkenyl or alkynyl defined in R6, if substituted, is substituted with one or more substituent/s selected from -OR 61 , halogen, -CN, haloalkyl, haloalkoxy and -NR6iR6r; wherein R 61 and R6r are independently selected from hydrogen, substituted or unsubstituted Ci-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkyl heterocyclyl; wherein the alkyl, alkenyl or alkynyl defined in R 7 , if substituted, is substituted with one or more substituent/s selected from -OR 71 , halogen, -CN, haloalkyl, haloalkoxy and -NR71R71'; wherein the cycloalkyl, aryl and heterocyclyl, as defined in R 7 , also in
  • the compound according to the invention of general Formula (I) is a compound wherein
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkyl heterocyclyl; wherein the alkyl, alkenyl or alkynyl defined in R 7 , if substituted, is substituted with one or more substituent/s selected from -O R71 , halogen, -CN, haloalkyl, haloalkoxy and -N R71 R71 '; wherein the cycloalkyl, aryl and heterocyclyl, as defined in R 7 , also in alkylcycloalkyl, alkylaryl and alkylheterocyclyl, if substituted, is
  • R 14 , Ru ⁇ and Ru ⁇ are independently selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein the aryl or heterocyclyl in R 2 , if substituted, is substituted with one or more substituent/s selected from halogen, -R21, -OR21, -NO2, -NR21R21', -
  • R 21 , R 21' and R 21 are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate
  • the compound according to the invention of general Formula (I) is a compound wherein the alkyl, alkenyl or alkynyl defined in R3', if substituted, is substituted with one or more substituent/s selected from -OR 32 , halogen, -CN, haloalkyl, haloalkoxy and -NR32R32'; wherein R 32 and R 32' are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein the alkyl, alkenyl or alkynyl defined in R 6 , if substituted, is substituted with one or more substituent/s selected from -OR61, halogen, -CN, haloalkyl, haloalkoxy and - NR 6i R 6i' !
  • CN haloalkyl, haloalkoxy, -C(0)0R 7i , -C(0)NR 7i R7r, -OCH 2 CH 2 OR 7i ,
  • NR2iS(0) 2 NR2i'R 2i” and -C(CH3)20R 2I optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the according to the invention of general Formula (I) is a compound wherein the alkyl, alkenyl or alkynyl defined in R 3 , is substituted with one or more substituent/s selected from -O R31 , halogen, -CN, haloalkyl, haloalkoxy and -N R31 R31 '; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the according to the invention of general Formula (I) is a compound wherein the alkyl, alkenyl or alkynyl defined in R 3' , if substituted, is substituted with one or more substituent/s selected from -OR 32 , halogen, -CN, haloalkyl, haloalkoxy and -
  • NR32R32I optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the according to the invention of general Formula (I) is a compound wherein the alkyl, alkenyl or alkynyl defined in R 6 , if substituted, is substituted with one or more substituent/s selected from -OR 61 , halogen, -CN, haloalkyl, haloalkoxy and -NR6iR6r; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the according to the invention of general Formula (I) is a compound wherein the alkyl, alkenyl or alkynyl defined in R 7 , if substituted, is substituted with one or more substituent/s selected from -OR71, halogen, -CN, haloalkyl, haloalkoxy and -NR71R71'; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • X is a bond, -[C(R a Rb)] P -, -[C(R a Rb)]pC(0)[C(R c Rd)] q -, -[C(R a Rb)] P C(0)N(R z )[C(R c Rd)] q - , [C(R a Rb)]pN(R z )C(0)[C(RcRd)] q - or -[C(R a R b )] P N(R z )[C(R c Rd)] q -;
  • R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C2- 6 alkenyl, substituted or unsubstituted C2- 6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl;
  • R a is selected from hydrogen, halogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C2- 6 alkenyl and substituted or unsubstituted C2- 6 alkynyl;
  • R b is selected from hydrogen, halogen, substituted or unsubstituted C1- 6 alkyl, substituted or unsubstituted C2- 6 alkenyl and substituted or unsubstituted C2- 6 alkynyl; alternatively, R a and R b , taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl; R c is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2- 6 alkenyl and substituted or unsubstituted C2- 6 alkynyl;
  • R d is selected from hydrogen, substituted or unsubstituted C1- 6 alkyl, substituted or unsubstituted C2- 6 alkenyl and substituted or unsubstituted C2- 6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • X is a bond, -[C(R a Rb)] P -, -[C(RaRb)] P C(0)[C(R c Rd)] q -, -[C(R a Rb)] P C(0)N(R z )[C(R c Rd)] q - , [C(R a Rb)] P N(R z )C(0)[C(RcRd)] q - or -[C(R a R b )] P N(R z )[C(R c Rd)] q -; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the according to the invention of general Formula (I) is a compound wherein
  • R a is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C2-6 alkenyl and substituted or unsubstituted C2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • Rb is selected from hydrogen, halogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl and substituted or unsubstituted C2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • R a and R b taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • R c is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C2-6 alkenyl and substituted or unsubstituted C2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • R d is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl and substituted or unsubstituted C2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ]pC(0)N(Rz)[CH 2 ] q -, - [CH2]pN(R z )C(0)[CH2] q - and -[CH2] N(R z )[CH2] q -; preferably X is selected from a bond,
  • R a is selected from hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; preferably R a is hydrogen; and/or
  • R b is selected from hydrogen, halogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; preferably R b is hydrogen; and/or
  • R a and R b taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl; and/or R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; preferably R z is selected from hydrogen and substituted or unsubstituted Ci- 6 alkyl; more preferably R z is selected from hydrogen, substituted or unsubstituted methyl; and/or
  • p is 0, 1 , 2, 3, 4 or 5; preferably p is 0, 1 or 2; and/or
  • q is 0, 1 , 2, 3, 4 or 5; preferably q is 0, 1 or 2; and/or
  • Yi is -C(RioRio')-; preferably Yi is -CH2-; and/or
  • Y2 is -C(RioRio')-; preferably Y2 is -CH2-; and/or
  • n 0 or 1 ;
  • n 0, 1 or 2; preferably m is 1 ;
  • r is 0, 1 or 2; preferably r is 1 ;
  • R 2 is selected from substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; preferably R 2 is selected from substituted or unsubstituted aryl and substituted or unsubstituted aromatic heterocyclyl, more preferably R 2 is a substituted or unsubstituted group selected from phenyl and thiophen; and/or
  • R 3 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted alkylcycloalkyl; preferably R 3 is substituted or unsubstituted C 1-6 alkyl; more preferably R 3 is substituted or unsubstituted methyl; and/or
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl; preferably R 3' is hydrogen; and/or
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -NO2, -NR 4i R 4 r, - NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 -rR 4 -r, -SR 4 I , -S(0)R 4i , - S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , -C(0)NR 4i R 4 r, -0CH 2 CH 2 0R 4 I , - NR 4i S(0) 2 NR 4i ' R 4i” and -C(CH 3 ) 2 0R 4 I ; preferably R 4 and R 4 ⁇ are both -R 4 I , more preferably R 4 and R 4 ⁇ are both hydrogen; and/or
  • R5 and R5' are independently selected from halogen, -R51, -OR51, -NO2, -NR51R51', - NR 5i C(0)R 5 r, -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 r, - NR 5i C(0)NR 5 rR 5i ⁇ , -SR 5 I , -S(0)R 5i , -S(0)2R5i, -CN, haloalkyl, haloalkoxy, -C(0)0Rsi, -C(0)NR 5i R5r, -OCH2CH2OR51, - NR 5i S(0) 2 NR 5 rR 5 r and -C(CH3)20R5i; preferably R5 and Rs ⁇ are both hydrogen or R 5 is -OH while Rs ⁇ is hydrogen; and/or
  • R 6 is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R 7 ; preferably R 6 is selected from hydrogen and substituted or unsubstituted C1-6 alkyl; more preferably R 6 is selected from hydrogen and substituted or unsubstituted methyl; and/or
  • R7 is selected from substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl;
  • Rg and Rg ⁇ are independently selected from halogen, -R21, -OR21, -NO2, -NR21R21', - NR 2i C(0)R 2 r, -NR 2i S(0) 2 R 2 r, -S(0) 2 NR 2i R2r, - NR 2i C(0)NR 2 rR2r, -SR21 , -S(0)R 21 , -S(0) 2 R 2 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 2i , -C(0)NR 2i R 2 r, -OCH2CH2OR21, -
  • Rg and Rg ⁇ are both -R21; more preferably Rg and Rg ⁇ are both hydrogen; and/or
  • R 10 and Rio ⁇ are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted
  • R 10 and Rio are both hydrogen; and/or Rio and R-io form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl; and/or
  • Rio and Rio are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; preferably Rio- and Rio- are both hydrogen; and/or
  • R 10 and Rio form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl; and/or
  • R 13 and Ri 3' are independently selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl and unsubstituted C 2-6 alkynyl; and/or
  • R 14 , Ri 4’ and R-u- are independently selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl; and/or
  • R 21 , R 21' and R 21” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; and/or
  • R 31 , R 31' and R 31 " are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; and/or R 32 and R 32' are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl; and/or R 41 , R 41’ and R 41” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl and substituted or unsubstituted cycloalkyl; preferably R 41 is hydrogen; and/or R 51 , R 51' and Rsr are independently selected from hydrogen, substituted or unsubsti
  • R 61 , R 61' and R 6 r are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; and/or
  • R 71 , R 71’ and R 71 are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound according to the invention of general Formula (I) is a compound wherein X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -;
  • p 0, 1 , 2, 3, 4 or 5;
  • q 0, 1 , 2, 3, 4 or 5;
  • n 0 or 1 ;
  • Y 2 is -C(Rio”Rio )-;
  • n 0, 1 or 2;
  • r is 0, 1 or 2;
  • R b is selected from hydrogen, halogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; wherein the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne;
  • R a and R t> taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl; wherein the cycloalkyl is C3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C3-6 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
  • R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; wherein the alkyl is C1-6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2- methylpropyl; and/or the C1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; more preferably the C1-6 alkyl is methyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene,
  • R 2 is selected from substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; wherein the aryl is selected from phenyl, naphthyl, or anthracene; preferably is naphthyl and phenyl; preferably the aryl is phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from oxazepan, pyrrolidine, imidazole, oxadiazole, tetrazole, azetidine, pyridine, pyrimidine, piperidine
  • R3 is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted alkylcycloalkyl; wherein
  • the alkyl is C1-6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2- methylpropyl; and/or the C1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; preferably the C1-6 alkyl is methyl; and/or the C2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or the cycloalkyl is C 3-8 cycloalky
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; wherein the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne;
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -N0 2 , -NR 4i R 4 r, - NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 -rR 4 -r, -SR 4 I , -S(0)R 4i , - S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , -C(0)NR 4i R 4 r, -OCH 2 CH 2 OR 4 I , - NR 4i S(0) 2 NR 4i ' R 4i” and -C(CH3) 2 OR 4 I ; wherein
  • the alkyl is Ci- 6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2- methylpropyl;
  • R5 and R5' are independently selected from halogen, -R51, -OR51, -NO2, -NR51R51', - NR 5i C(0)R 5 r, -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 r, - NR 5i C(0)NR 5 rR 5i ⁇ , -SR 5 I , -S(0)R 5i , -S(0) 2 R5i, -CN, haloalkyl, haloalkoxy, -C(0)0Rsi, -C(0)NR 5i R5r, -OCH 2 CH 2 OR5i, - NR 5i S(0) 2 NR 5 rR 5 r' and -C(CH 3 ) 2 OR 5i ; wherein
  • the alkyl is C1-6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2- methylpropyl;
  • R 6 is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R ? ;
  • alkyl is Ci- 6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2- methylpropyl; and/or the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; preferably the Ci- 6 alkyl is methyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or the cycloalkyl is C 3-8
  • R7 is selected from substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl;
  • alkyl is C1-6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2- methylpropyl; and/or the C1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or the cycloalkyl is C3-8 cycloalkyl like cyclopropyl, cycloprop
  • Rg and Rg ⁇ are independently selected from halogen, -R21, -OR21, -NO2, -NR21R21', - NR 2i C(0)R 2 r, -NR 2i S(0) 2 R 2 r, -S(0) 2 NR 2i R2r, - NR 2i C(0)NR 2 rR2r, -SR21 , -S(0)R 21 , -S(0)2R2i, -CN, haloalkyl, haloalkoxy, -C(0)0R2i, -C(0)NR2iR2r, -OCH2CH2OR21, - NR 2i S(0) 2 NR 2 rR2i” and -C(CH3)20R2i wherein the alkyl is C 1-6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2- methylpropyl; and/or
  • R 10 and Rio ⁇ are independently selected from hydrogen, substituted or unsubstituted
  • the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne;
  • R 10 and R-io' form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl; wherein the cycloalkyl is C 3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C 3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C 3-6 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or R 10” and R-io- are independently selected from hydrogen, substituted or unsubstituted
  • the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or
  • R 10 and R-io- form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl;
  • the cycloalkyl is C 3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C 3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C 3-6 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; and/or R 13 and R 13' are independently selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl and unsubstituted C 2-6 alkynyl;
  • the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or
  • R 14 , R I4 ⁇ and R-u- are independently selected from hydrogen, unsubstituted C 1-6 alkyl, unsubstituted C 2-6 alkenyl, unsubstituted C 2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl; wherein
  • the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or the cycloalkyl is C3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C3-7 cycloalkyl like cyclopropy
  • R 21 , R 21' and R 21” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; wherein
  • the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, more preferably the C 1-6 alkyl is methyl, ethyl or propyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne;
  • R 31 , R 31' and R 31 " are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; wherein the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne;
  • R 32 and R 32' are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted
  • C2-6 alkynyl wherein the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne;
  • R 41 , R 41’ and R 41 are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl and substituted or unsubstituted cycloalkyl; wherein
  • the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, more preferably the C 1-6 alkyl is methyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or the cycloalkyl is C 3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C
  • R 51 , R 51' and R 51 " are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; wherein
  • the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne;
  • R 61 , R 61' and R 6 r are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; wherein the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, more preferably the C 1-6 alkyl is methyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne
  • R 71 , R 71’ and R 71 are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl;
  • the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a
  • the compound is a compound, wherein in R a as defined in any of the embodiments of the present invention, the C1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne;
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein in R b as defined in any of the embodiments of the present invention, the C1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne;
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein in R a -R b as defined in any of the embodiments of the present invention, the cycloalkyl is C 3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C 3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C 3-6 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein in R z as defined in any of the embodiments of the present invention, the alkyl is C 1-6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2- methylpropyl; and/or the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; more preferably the C 1-6 alkyl is methyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyl, or 2-methylpropyl; and/or the
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein in F3 ⁇ 4 as defined in any of the embodiments of the present invention, the aryl is selected from phenyl, naphthyl, or anthracene; preferably is naphthyl and phenyl; preferably the aryl is phenyl; and/or the heterocyclyl is a heterocyclic ring system of one or more saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring; preferably is a heterocyclic ring system of one or two saturated or unsaturated rings of which at least one ring contains one or more heteroatoms selected from the group consisting of nitrogen, oxygen and/or sulfur in the ring, more preferably is selected from oxazepan, pyrrolidine, imidazole, oxadiazole, tetrazole, azetidine, pyridine, pyr
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein in Rs as defined in any of the embodiments of the present invention, the alkyl is Ci- 6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2- methylpropyl; and/or the C alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; preferably the Ci- 6 alkyl is methyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, he
  • the compound is a compound, wherein in F ⁇ as defined in any of the embodiments of the present invention, the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers,
  • the compound is a compound, wherein in R 4 and R 4 ⁇ as defined in any of the embodiments of the present invention, the alkyl is Ci- 6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2- methylpropyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the alkyl is Ci- 6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2- methylpropyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers
  • the compound is a compound, wherein in R 5 and R 5 ⁇ as defined in any of the embodiments of the present invention, the alkyl is Ci- 6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2- methylpropyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the alkyl is Ci- 6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2- methylpropyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers
  • the compound is a compound, wherein in F3 ⁇ 4 as defined in any of the embodiments of the present invention, the alkyl is Ci- 6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2- methylpropyl; and/or the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; preferably the Ci- 6 alkyl is methyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyl
  • the compound is a compound, wherein in R 7 as defined in any of the embodiments of the present invention, the alkyl is Ci- 6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2- methylpropyl; and/or the C alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and
  • the compound is a compound, wherein in Rg and Rg ⁇ as defined in any of the embodiments of the present invention, the alkyl is Ci- 6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2- methylpropyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the alkyl is Ci- 6 alkyl like methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2- methylpropyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers,
  • the compound is a compound, wherein in Rio and Rio ⁇ as defined in any of the embodiments of the present invention, the C1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne;
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein in Rio and Rio ⁇ as defined in any of the embodiments of the present invention, the cycloalkyl is C 3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C 3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C 3-6 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantio
  • the compound is a compound, wherein in Rio- and R 10” as defined in any of the embodiments of the present invention, the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne;
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein in Rio- and R 10” as defined in any of the embodiments of the present invention, the cycloalkyl is C 3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C 3-7 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl; more preferably from C 3-6 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl;
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein in R 13 and R 13' as defined in any of the embodiments of the present invention, the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne;
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein in R-u, R-u ⁇ and R-u- as defined in any of the embodiments of the present invention, the C1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or the cycloalkyl is C 3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopen
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein in R21, R 2 r and R21” as defined in any of the embodiments of the present invention, the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, more preferably the C 1-6 alkyl is methyl, ethyl or propyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; optionally in form of one of the stereoisomers, preferably
  • the compound is a compound, wherein in R 31 , R 31' and R 31” as defined in any of the embodiments of the present invention,
  • the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate
  • the compound is a compound, wherein in R32 and R32' as defined in any of the embodiments of the present invention,
  • the C1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof
  • the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, more preferably the C 1-6 alkyl is methyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; and/or the cycloalkyl is C 3-8 cycloalkyl like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; preferably is C
  • the compound is a compound, wherein in R 51 , Rsr and R 5 r as defined in any of the embodiments of the present invention, the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C 2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of
  • the compound is a compound, wherein in [3 ⁇ 4i, R 6 r and Rev as defined in any of the embodiments of the present invention,
  • the C 1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl, more preferably the C 1-6 alkyl is methyl; and/or the C 2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or
  • the compound is a compound, wherein in R71 , R71 ' and R 7 r as defined in any of the embodiments of the present invention,
  • the C1-6 alkyl is preferably selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, or 2-methylpropyl; and/or the C2-6 -alkenyl is preferably selected from ethylene, propylene, butylene, pentylene, hexylene, isopropylene and isobutylene; and/or the C2-6 -alkynyl is preferably selected from ethyne, propyne, butyne, pentyne, hexyne, isopropyne and isobutyne; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof
  • the compound is a compound, wherein p is 0, 1 , 2, 3, 4 or 5; preferably p is 0, 1 or 2; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein q is 0, 1 , 2, 3, 4 or 5; preferably q is 0, 1 or 2; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein n is 0 or 1 ; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein m is 0, 1 or 2; preferably m is 1 ; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein r is 0, 1 or 2; preferably r is 1 ; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • X is selected from a bond, -[C(R a Rb)] P -, -[CH 2 ]pC(0)[CH 2 ] q -, -[CH 2 ] p C(0)N(R z )[CH 2 ] q -, - [CH 2 ] p N(R z )C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )[CH 2 ] q -; preferably X is selected from a bond, -[C(R a R b )]p-, -[CH 2 ] p C(0)[CH 2 ] q - and -[CH 2 ] p N(R z )C(0)[CH 2 ] q ; more preferably selected from a bond, -CH 2 -, -CH 2 CH 2 -, -C(O)-, -NHC(0)CH 2 -, -NHC(0)CH 2 CH
  • R a is selected from hydrogen, halogen, substituted or unsubstituted Ci-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; preferably R a is hydrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • R b is selected from hydrogen, halogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; preferably R b is hydrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • R a and R b taken together with the carbon atom to which they are attached, form a substituted or unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • the compound is a compound, wherein
  • Yi is -C(RioRio')-; preferably Y1 is -CH2-; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • Y2 is -C(RioRio')-; preferably Y2 is -CH2-; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • R z is selected from hydrogen, substituted or unsubstituted Ci- 6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl and -C(0)-Ci- 6 alkyl; preferably R z is selected from hydrogen and substituted or unsubstituted C 1-6 alkyl; more preferably R z is selected from hydrogen, substituted or unsubstituted methyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • R 2 is selected from substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl; preferably R 2 is selected from substituted or unsubstituted aryl and substituted or unsubstituted aromatic heterocyclyl, more preferably R 2 is a substituted or unsubstituted group selected from phenyl and thiophen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein R 3 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted alkylcycloalkyl; preferably R 3 is substituted or unsubstituted C 1-6 alkyl; more preferably R 3 is substituted or unsubstituted methyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • R 3 is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substitute
  • the compound is a compound, wherein
  • R 3' is selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; preferably R 3' is hydrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • R 4 and R 4' are independently selected from halogen, -R 4 I , -OR 4 I , -NO2, -NR 4i R 4 r, - NR 4i C(0)R 4 r, -NR 4i S(0) 2 R 4 r, -S(0) 2 NR 4i R 4 r, -NR 4i C(0)NR 4 -rR 4 -r, -SR 4 I , -S(0)R 4i , - S(0) 2 R 4 I , -CN, haloalkyl, haloalkoxy, -C(0)0R 4i , -C(0)NR 4i R 4 r, -OCFhCFhOR ⁇ , -
  • the compound is a compound, wherein
  • R5 and R5' are independently selected from halogen, -R51, -OR51, -NO2, -NR51R51', - NR 5i C(0)R 5 r, -NR 5i S(0) 2 R 5 r, -S(0) 2 NR 5i R 5 r, - NR 5i C(0)NR 5 rR 5i ⁇ , -SR 5I , -S(0)R 5i , -S(0) 2 R5i, -CN, haloalkyl, haloalkoxy, -C(0)0Rsi, -C(0)NR 5i R5r, -OCH 2 CH 2 OR5i, - NR 5i S(0) 2 NR 5 rR 5 r and -C(CH3) 2 OR5i; preferably R5 and Rs ⁇ are both hydrogen or R 5 is -OH while Rs ⁇ is hydrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in
  • the compound is a compound, wherein
  • R 6 is selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl and -C(0)R 7 ; preferably R 6 is selected from hydrogen and substituted or unsubstituted C1-6 alkyl; more preferably R 6 is selected from hydrogen and substituted or unsubstituted methyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers,
  • R 7 is selected from substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkylheterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • Rg and Rg ⁇ are independently selected from halogen, -R21, -OR21, -NO2, -NR21R21', - NR 2i C(0)R 2 r, -NR 2i S(0) 2 R 2 r, -S(0) 2 NR 2i R2r, - NR 2i C(0)NR 2 rR2r, -SR21 , -S(0)R 21 , -S(0)2R2i, -CN, haloalkyl, haloalkoxy, -C(0)0R2i, -C(0)NR2iR2r, -OCH2CH2OR21, - NR2iS(0) 2 NR 2 rR2r and -C(CH3)20R2i preferably Rg and Rg ⁇ are both -R21; more preferably Rg and Rg ⁇ are both hydrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of
  • the compound is a compound, wherein
  • R10 and Rio ⁇ are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl and substituted or unsubstituted C2-6 alkynyl; preferably R10 and Rio are both hydrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • R 10 and Re form, with the carbon atom to which they are attached, a substituted or unsubstituted cycloalkyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • Rio” and Rio- are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; preferably Rio- and Rio- are both hydrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • the compound is a compound, wherein
  • R13 and Ri3' are independently selected from hydrogen, unsubstituted Ci- 6 alkyl, unsubstituted C2-6 alkenyl and unsubstituted C2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • R14, Ri4’ and R-u- are independently selected from hydrogen, unsubstituted C1-6 alkyl, unsubstituted C2-6 alkenyl, unsubstituted C2-6 alkynyl, unsubstituted aryl, unsubstituted cycloalkyl and unsubstituted heterocyclyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein R 21 , R 21' and R 21” are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • R 31 , R 31' and R 31 " are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • R 32 and R 32' are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • R 41 , R 41’ and R 41 are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, substituted or unsubstituted C 2-6 alkynyl and substituted or unsubstituted cycloalkyl; preferably R 41 is hydrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • R 51 , R 51' and R 51 " are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl, and substituted or unsubstituted C 2-6 alkynyl; preferably R 51 is hydrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • R 61 , R 61' and Rev are independently selected from hydrogen, substituted or unsubstituted C 1-6 alkyl, substituted or unsubstituted C 2-6 alkenyl and substituted or unsubstituted C 2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein
  • R71 , R71’ and R71 are independently selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compound is a compound, wherein p is 0, 1 or 2; and/or q is 0, 1 or 2; and/or n is 0 or 1 ; and/or m is 1 ; and/or r is 1 ; and/or
  • X is selected from a bond, -CH 2 -, -CH 2 CH 2 -, -C(O)-, -NHC(0)CH 2 -, -NHC(0)CH 2 CH 2 - and -N(CH 3 )C(0)CH 2 -; and/or Y is -CH 2 -; and/or Yi is -CH 2 -; and/or Y 2 is -CH 2 -; and/or
  • R a is hydrogen
  • Rb is hydrogen; and/or R 2 is a substituted or unsubstituted group selected from phenyl and thiophen; and/or
  • R 3 is substituted or unsubstituted methyl
  • R 3' is hydrogen
  • R 4 and R 4' are both hydrogen; and/or
  • R 5 and R 5' are both hydrogen or R 5 is -OH while R 5 ⁇ is hydrogen;
  • R 6 is selected from hydrogen and substituted or unsubstituted methyl
  • Rg and Rg ⁇ are both hydrogen; and/or
  • Rio” and Rio- are both hydrogen; and/or R 41 is hydrogen; and/or
  • R 51 is hydrogen; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • p is 0, 1 or 2.
  • q is 0, 1 or 2.
  • n is 0 or 1. In a preferred embodiment m is 1.
  • r is 1. In a preferred embodiment m and r are both 1.
  • X is selected from a bond, -CH 2 -, -CH 2 CH 2 -, -C(O)-, -NHC(0)CH 2 -, -NHC(0)CH 2 CH 2 - and -N(CH 3 )C(0)CH 2 -.
  • X is selected from a bond, -CH 2 -, -CH 2 CH 2 -, -C(O)-, -NHC(0)CH 2 -, -NHC(0)CH 2 CH 2 - and -N(CH 3 )C(0)CH 2 -.
  • R a is hydrogen
  • Rb is hydrogen
  • R a and R b are both hydrogen.
  • Y is -CH2-.
  • Yi is -CH2-.
  • Y 2 is -CH2-.
  • Yi and Y2 are both -CH2-.
  • R 2 is selected from substituted or unsubstituted aryl and substituted or unsubstituted aromatic heterocyclyl, more preferably R 2 is a substituted or unsubstituted group selected from phenyl and thiophen.
  • R 3 is substituted or unsubstituted C 1-6 alkyl; more preferably R 3 is substituted or unsubstituted methyl. In a preferred embodiment
  • R 3' is hydrogen
  • R 3 is substituted or unsubstituted C 1-6 alkyl; more preferably R 3 is substituted or unsubstituted methyl while R 3' is hydrogen. In a preferred embodiment
  • R 4 is hydrogen
  • R 4' is hydrogen
  • R 4 and R 4' are both hydrogen.
  • R 5 is hydrogen or -OH.
  • R 5 is hydrogen or -OH, while R 5 ⁇ is hydrogen.
  • R 6 is selected from hydrogen and substituted or unsubstituted methyl.
  • Rg and Rg ⁇ are both hydrogen.
  • R 10 and Rio are both hydrogen.
  • R 10 and R 10 - are both hydrogen.
  • R10, Rio ⁇ , R10” and Rio- are all hydrogen.
  • R 41 is hydrogen
  • R 51 is hydrogen.
  • the halogen is fluorine, chlorine, iodine or bromine.
  • halogen is fluorine
  • haloalkyl is -CF 3 .
  • haloalkoxy is -OCF 3 .
  • the compounds of the general Formula (I) are selected from optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • the compounds are selected which act as dual ligands of the a2d subunit, particularly the a2d-1 subunit, of the voltage-gated calcium channel and the m-opioid receptor and especially compounds which have a binding expressed as K, responding to the following scales:
  • Ki(p) is preferably ⁇ 1000 nM, more preferably ⁇ 500 nM, even more preferably ⁇ 100 nM.
  • K ⁇ (a2d1 ) is preferably ⁇ 10000 nM, more preferably ⁇ 5000 nM, even more preferably ⁇ 500 nM.
  • a preferred embodiment of the invention is a process for the production of a compound according to Formula (I), wherein, if not defined otherwise, R 1 , R 2 , R 3 , R 3' , R 4 , R 4' , X, Ui, Y2 and n have the meanings defined in the description.
  • LG represents a leaving group (such as chloro, bromo, iodo, mesylate, tosylate, nosylate or triflate).
  • M represents a suitable organometallic group, preferably a boron or zinc reagent, and p has the meaning as defined in the description.
  • p has the meaning as defined in the description.
  • LG represents a leaving group such as chloro, bromo, iodo, mesylate, tosylate, nosylate or triflate, p, q and Rz have the meanings as defined in the description, with a /V-containing cyclic reagent of formula (ill-1 )
  • said process comprises treating a compound of formula (I la),
  • M represents a suitable organometallic group, preferably a boron or zinc reagent, and p has the meaning as defined in the description;
  • LG represents a leaving group such as chloro, bromo, iodo, mesylate, tosylate, nosylate or triflate, p, q and Rz have the meanings as defined in the description, with a /V-containing cyclic reagent of formula (ill-1 )
  • said process comprises reacting a compound of formula (Vila) wherein G is OH,
  • said process comprises reacting a compound of formula (Vila) wherein G is OH,
  • said process comprises reacting a compound of formula (Vila) wherein G is halogen,
  • said process comprises reacting a compound of formula (VI lb) with an agent of formula (VIII), wherein either Z represents OH and G represents a leaving group such as chloro, bromo, iodo, mesylate, tosylate, nosylate or triflate, or alternatively Z represents a leaving group such as chloro, bromo, iodo, mesylate, tosylate, nosylate or triflate and G represents OH.
  • an amine protecting group such as a carbamate, preferably tert-butoxy carbonyl
  • a reductive reagent preferably sodium triacetoxyborohydride
  • an organic solvent preferably DCE
  • an organic base preferably DIPEA or TEA
  • the reaction can be carried out in the presence of an acid, preferably acetic acid.
  • a process for the production of a compound according to Formula (I), by reaction of a compound of formula I that contains an amino group with an alkylating reagent, in the presence of a base, preferably DIPEA or K 2 CO 3 , in an organic solvent, preferably acetonitrile, at suitable temperature, such as in the range of 0-120 °C.
  • a base preferably DIPEA or K 2 CO 3
  • organic solvent preferably acetonitrile
  • R 2 , R3, R3', R 4 , R 4 ⁇ , Y-i, Y2 and n have the meanings as defined in the description, for the preparation of compounds of Formula (I).
  • a particular embodiment of the invention refers to the use of a compound of Formula (I la),
  • a particular embodiment of the invention refers to the use of a compound of Formula (lla-LG),
  • LG represents a leaving group such as chloro, bromo, iodo, mesylate, tosylate, nosylate or triflate
  • Q represents chloro, bromo, iodo or triflate
  • R 2 , R 4 , R 4 ⁇ , Yi, Y 2 and n have the meanings as defined in the description, for the preparation of compounds of Formula (I).
  • a particular embodiment of the invention refers to the use of a compound of Formula (lib),
  • R 2 , R 3 , R 3' , R 4 , R 4 ⁇ , Yi, Y 2 , n and r have the meanings as defined in the description, for the preparation of compounds of Formula (I).
  • a particular embodiment of the invention refers to the use of a compound of Formula (lib’),
  • R a , Rb, R 2 , R3, R3’, R 4 , R 4 ⁇ , Yi, Y 2 , n and r have the meanings as defined in the description, for the preparation of compounds of Formula (I).
  • LG represents a leaving group such as chloro, bromo, iodo, mesylate, tosylate, nosylate or triflate
  • R 2 , R 4 , R 4 ⁇ , Yi, Y 2 , n and r have the meanings as defined in the description, for the preparation of compounds of Formula (I).
  • a particular embodiment of the invention refers to the use of a compound of Formula (llb’-LG),

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des dérivés d'aminopropoxyphényle et de benzyl 3,4-dihydro-2H- spiro[isoquinoline-1,4'-pipéridine]-1'-yl présentant une activité pharmacologique double à la fois envers la sous-unité α2δ, en particulier la sous-unité α2δ-1, du canal calcique sensible à la tension et du récepteur opioïde µ, des procédés de préparation de ces composés, des compositions pharmaceutiques les comprenant, ainsi que leur utilisation thérapeutique, en particulier pour traiter la douleur.
PCT/EP2019/057186 2018-03-23 2019-03-22 Dérivés d'aminopropoxyphényle et de benzyl 3,4-dihydro-2h-spiro[isoquinoline-1,4'-pipéridine]-1'-yl ayant une activité multimodale contre la douleur Ceased WO2019180189A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382202 2018-03-23
EP18382202.2 2018-03-23

Publications (1)

Publication Number Publication Date
WO2019180189A1 true WO2019180189A1 (fr) 2019-09-26

Family

ID=61768243

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/057186 Ceased WO2019180189A1 (fr) 2018-03-23 2019-03-22 Dérivés d'aminopropoxyphényle et de benzyl 3,4-dihydro-2h-spiro[isoquinoline-1,4'-pipéridine]-1'-yl ayant une activité multimodale contre la douleur

Country Status (1)

Country Link
WO (1) WO2019180189A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016078770A1 (fr) 2014-11-21 2016-05-26 Laboratorios Del Dr. Esteve, S.A. Composés de spiro-isoquinoline-1,4'-pipéridine à activité multimodale contre la douleur
WO2016177472A1 (fr) * 2015-05-05 2016-11-10 Laboratorios Del Dr. Esteve, S.A. Composés de spiro-isoquinoline-4,4'-pipéridine à activité multimodale contre la douleur

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016078770A1 (fr) 2014-11-21 2016-05-26 Laboratorios Del Dr. Esteve, S.A. Composés de spiro-isoquinoline-1,4'-pipéridine à activité multimodale contre la douleur
WO2016177472A1 (fr) * 2015-05-05 2016-11-10 Laboratorios Del Dr. Esteve, S.A. Composés de spiro-isoquinoline-4,4'-pipéridine à activité multimodale contre la douleur

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
"Progress in Pain Research and Management", vol. 25, 2003, IASP PRESS, article "Opioids and Pain Relief: A Historical Perspective"
BIOCHIM BIOPHYS ACTA, vol. 1828, 2013, pages 1541 - 9
BORNOT A; BAUER U; BROWN A; FIRTH M; HELLAWELL C; ENGKVIST O: "Systematic Exploration of Dual-Acting Modulators from a Combined Medicinal Chemistry and Biology Perspective", J. MED. CHEM, vol. 56, 2013, pages 1197 - 1210
DAVIES ET AL., TRENDS PHARMACOL SCI., vol. 28, 2007, pages 220 - 8
DICKENSON, A.H.; SUZUKI, R.: "Opioids in neuropathic pain: Clues from animal studies", EUR J PAIN, vol. 9, 2005, pages 113 - 6, XP004767581, DOI: doi:10.1016/j.ejpain.2004.05.004
DOLPHIN AC, NAT REV NEUROSCI., vol. 13, 2012, pages 542 - 55
GILRON ET AL., LANCET NEUROL., vol. 12, no. 11, November 2013 (2013-11-01), pages 1084 - 95
GOLDBERG, D.S.; MCGEE, S.J., BMC PUBLIC HEALTH, vol. 11, 2011, pages 770
HOPKINS, NAT CHEM BIOL., vol. 4, 2008, pages 682 - 90
J PHARMACOL EXP THER., vol. 342, 2012, pages 232
KROGSGAARD-LARSEN ET AL.: "Textbook of Drug design and Discovery", April 2002, TAYLOR & FRANCIS
LEHAR ET AL., NAT BIOTECHNOL, vol. 27, 2009, pages 659 - 666
MAO, J.; GOLD, M.S.; BACKONJA, M., J. PAIN, vol. 12, 2011, pages 157 - 166
NEUMAIER ET AL., PROG NEUROBIOL., vol. 129, 2015, pages 1 - 36
PERRET; LUO, NEUROTHERAPEUTICS, vol. 6, 2009, pages 679 - 92
SCHRODER ET AL., J PHARMACOL EXP THER., vol. 337, 2011, pages 312 - 20
TURK, D.C.; WILSON, H.D.; CAHANA, A., LANCET, vol. 377, 2011, pages 2226 - 2235
VINK; ALEWOOD, BR J PHARMACOL., vol. 167, 2012, pages 970 - 89
ZAMPONI ET AL., PHARMACOL REV., vol. 67, 2015, pages 821 - 70
ZHANG ET AL., CELL DEATH DIS., vol. 5, 2014, pages e1138

Similar Documents

Publication Publication Date Title
EP3442960A1 (fr) Dérivés d'arylamide ayant une activité multimodale contre la douleur
EP3442959A1 (fr) Dérivés de pipéridinylalkylamide ayant une activité multimodale contre la douleur
JP2017516817A (ja) 疼痛に対する多様な活性を有する１−オキサ−４，９−ジアザスピロウンデカン化合物のアミド誘導体
EP3478665A1 (fr) Dérivés de pyrazole ayant une activité contre la douleur
KR20230017828A (ko) 통증에 대한 다중모드 활성을 갖는 피라졸로[1,5-a]피리미딘 유도체
WO2020021021A1 (fr) Dérivés de phénoxypropylamino et de benzyloxypropylamino ortho-substitués présentant une activité multimodale contre la douleur
JP2017535566A (ja) 疼痛に対する多様な活性を有する１，９−ジアザスピロウンデカン化合物
US12479830B2 (en) Homopiperazinyl and homopiperidinyl quinazolin-4(3H)-one derivatives having multimodal activity against pain
KR20250069710A (ko) 약물 남용 및 중독 치료를 위한 옥사디아자스피로 화합물
EP3873895A1 (fr) Dérivés de pipérazinyle et de pipéridinyl quinazolin-4 (3h)-one ayant une activité contre la douleur
WO2020089397A1 (fr) Dérivés de quinazolin-4(3h)-one substitués présentant une activité multimodale contre la douleur
US10562908B2 (en) Ortho substituted phenylpyrazolo- and phenylpyrrolo-pyridazine derivatives having multimodal activity against pain
WO2019110137A1 (fr) Dérivés d'o-phénoxy et d'o-benzyloxypropylamino ayant une activité contre la douleur
EP3402779A1 (fr) Dérivés de 3-éthyl-3-phénylazépane ayant une activité multimodale contre la douleur
WO2019180188A1 (fr) Dérivés d'aminopropoxyphényle et de benzyl 1-oxa -4,9-diazaspiro-undécane ayant une activité multimodale contre la douleur
EP3548491A1 (fr) Dérivés de phénylpyrazolo- et phénylpyrrolo-pyridazine méta-substitués ayant une activité multimodale contre la douleur
EP3548490A1 (fr) Dérivés de 2-phényl -2 h-pyrazolo [3,4-d]pyridazine ayant une activité contre la douleur
WO2019002173A1 (fr) Composés ayant une activité multimodale contre la douleur
WO2019115008A1 (fr) Dérivés de dialkylaminoarylpipéridinyl-o-phénoxy et de o-benzyloxypropylamino présentant une activité multimodale contre la douleur
WO2019180189A1 (fr) Dérivés d'aminopropoxyphényle et de benzyl 3,4-dihydro-2h-spiro[isoquinoline-1,4'-pipéridine]-1'-yl ayant une activité multimodale contre la douleur
WO2020016315A1 (fr) Dérivés de dihydroindazole fusionnés ayant une activité multimodale contre la douleur
WO2019149919A1 (fr) Dérivés d'aminopropoxypipéridinylamido ayant une activité multimodale contre la douleur
CN111225901A (zh) 用于治疗疼痛和与疼痛相关的病症的丙胺衍生物
EP3858810A1 (fr) Dérivés de dialkylaminoarylcycloalkylamide ayant une activité multimodale contre la douleur
EP3858438A1 (fr) Dérivés de 3,4-dihydro-2h-spiro[isoquinoléine-1,4'-pipéridine]amide ayant une activité multimodale contre la douleur

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19714351

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19714351

Country of ref document: EP

Kind code of ref document: A1